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This thesis examines the government regulatory policy towards the pharmaceutical 
biotechnology sector (Biopharmaceutical), with focus on Similar Biotherapeutic Products 
(biosimilars).  Biosimilars are highly similar but not identical molecules that claim to have 
similar quality, safety and efficacy of original (innovator/ reference) products. They differ 
significantly from the chemical based medicines (conventional pharmaceuticals) that the 
main active substance is usually from a living organism (biological). Such critical products 
are high on the treatment guidelines recommended for complex diseases with high death and 
disability burdens. Biosimilars started accessing the Egyptian Market long time before the 
Government established a proper regulatory structure/pathway to regulate such products. It 
is expected that Biosimilars will start accessing the Egyptian market with high influx rate 
during the upcoming years as many originator biopharmaceuticals are losing patent 
protection between 2013-2020. Such influx requires progressive policy thinking and well-
resourced regulatory structures to properly regulate the complex pharmaceutical 
biotechnology market, ensure protection of public health, prevention of potential regulatory 
failures and promoting investment in local production for improving access to medicines. 
The thesis adopts a qualitative methodology using semi structured and in-depth interviews 
with experts from the concerned governmental regulatory agencies, the biopharmaceutical 
industry, special interest groups (lobbying bodies), clinicians, civil society and independent 
researchers. Analytical findings revealed potential for regulatory reforms and policy options 
were suggested across the three regulatory domains studied (regulatory pathway of 
biosimilars , pricing policy and intellectual property protection). 
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Chapter 1: Introduction  
This thesis is examining the government regulatory policy towards the private 
pharmaceutical biotechnology (biopharmaceutical) sector with focus on biosimilars. 
Biosimilars are highly similar but not identical molecules that claim to have the same 
quality, safety and efficacy of original (innovator/ reference) products. Biosimilars 
differ significantly from chemical based medicines (conventional pharmaceuticals) in 
the main active substance (from a living organism - biological origin, it has much 
complex molecular structures that can never claim to be of identical of original 
product molecule and consequently any change in the processes of manufacturing or 
change in production site may have significant impact on quality, safety and efficacy 
(QSE) of the product and hence on the health of the patient. The continuous 
advanced progress in scientific development makes it hard to avoid introducing 
amendments to manufacturing processes for reasons ranging from cutting costs to 
improving efficiency. This leads to inconsistencies in products attributes between 
each batch being produced and sometimes these inconsistencies occur within the 
same batch that needs to be mitigated. The significance for studying such critical 
products is that they are high on the treatment guidelines recommended for treatment 
of complex diseases associated with high death and disability burden. Diseases such 
as hepatitis C virus induced liver inflammation, several types of cancers, diabetes, 
some hormonal disturbances and a range of other diseases are relying on 
biopharmaceutical medicines (medicines developed using biotechnological 
techniques and with active ingredient coming from living organism) Illustration of 
some examples of disease categories treated using biopharmaceutical medicines 
(with biosimilars in development) are given in Table 1 below: 
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Table 1: Major Diseases treated with Biopharmaceutical products 
Disease category Name of molecule Innovator producer  
1. Rheumatoid 
Arithritis  
Etanercept (Enbril) Amgen+Pfizer (Joint venture) 
2. Anemia due to 
chronic Kidney 
disease 
Epoeitin Alfa (Eprex) Johnson and Johson+Amgen 
(Joint venture) 
3. Breast , Stomach, 
gastroesophegal 
junction cancers 
Trustazumab (Herceptin) Roche 
4. Leukemia and 
rheumatoid arithritis 
Rituximab (MabThera) Roche 
5. Decrease in immunity 
due to receiving 
cancer 
immunosuppressive 
treatment 
Pegfilgrastim (Neulasta) Amgen  
6. Treatment of 
hepatitis C induced 
liver inflammation 
Pegylated Interferon alpha 2- 
a (Pegasys) 
Roche 
 
Due to its high profitability Multinational companies and producers of 
original reference products are trying to build barriers against market access to 
biosimilars. Among such efforts is sponsoring legislations that prevents retail 
pharmacist from switching branded biological products with its biosimilar or forcing 
pharmacists to consult with physicians prior to doing so. “Two companies in the US 
Amgen and Genentech are lobbying to prevent biosimilars from using slogans such as “just 
like herceptin” or “Better than Rituxan” or “Avastin biosimilar” in their marketing or 
labels”(Nature Biotechnology,2013). Companies that produce the innovator product are 
themselves preparing biosimilars for their own products post patent expiry in 
collaboration with some generic producers yet claims on superior quality to other 
rival biosimilars will exist due to their experience in developing the original product. 
Table 2 below lists the different terms given to biosimilars in different countries. 
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Table 2: List of terms given to Biosimilars in different countries 
Country Term given for biosimilar 
USA Follow on proteins 
EMA Biosimilar 
WHO Similar Biological Medicinal Products 
Canada Follow on biologics 
Japan Subsequent entry proteins 
India Biogenerics 
Saudi  Biosimilars 
Egypt Biosimilars 
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Biosimilars started accessing the Egyptian Market almost a decade1 before the 
Government established a proper regulatory policy towards such products within the 
Ministry of Health. Currently around 55 biosimilar products with different 
concentrations and dosage forms ranging from Insulin’s, Interferon’s, erythropoietin’s 
and other essential or lifesaving products are manufactured and legally marketed in 
the Egyptian Market. Table 3 lists the biosimilars manufactured2 in Egypt with their 
registration license date and status 
Table 3: List of Biosimilars Manufactured and Registered in Egypt 
Reg. date License 
status 
Trade name Composition as mentioned in 
registration license 
Manufacturer name 
6/22/2004 VALID EPOJET 10000I.u./ml prefilled 
syringe 
  RECOMBINANT HUMAN 
ERYTHROPOIETIN-ALPHA 
VACSERA 
2/25/2003 VALID EPOJET 2000I.u./0.5ml    RECOMBINANT HUMAN 
ERYTHROPOIETIN-ALPHA 
VACSERA 
12/7/1999 VALID ERYPOIETIN 2000 I.U./vial ERYTHROPOIETIN AMOUN 
PHARMACEUTICAL 
INDUSTRIES Co. 
12/7/1999 VALID ERYPOIETIN 4000 I.U./vial ERYTHROPOIETIN AMOUN 
PHARMACEUTICAL 
INDUSTRIES Co. 
4/3/2001 VALID LEUCONIL 500µg /vial 
lyophilized vial 
GRANULOCYTE MACROFAGE 
COLONY STIMULATING 
FACTOR 
EL NILE. 
4/3/2001 VALID LEUCONIL 300 µg/vial 
lyophilized vial 
GRANULOCYTE MACROFAGE 
COLONY STIMULATING 
FACTOR 
EL NILE. 
4/3/2001 VALID LEUCONIL 150 µg/vial  
lyophilized vial 
GRANULOCYTE MACROFAGE 
COLONY STIMULATING 
FACTOR 
EL NILE. 
5/8/2001 VALID EGYFERON 1 M.I.U. vial INTERFERON ALFA-2b EL NILE. 
8/5/2001 VALID EGYFERON 3 M.I.U. vial INTERFERON ALFA-2b EL NILE. 
5/8/2001 VALID EGYFERON 5 M.I.U. vial INTERFERON ALFA-2b EL NILE. 
                                                            
1
 Biological products registration list in Egypt- 2013 
2
 Manufacturing may include secondary packaging 
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5/21/2002 VALID ERYPOIETIN 3000 I.U. vial  rhu-ERYTHROPOIETIN AMOUN 
PHARMACEUTICAL 
INDUSTRIES Co. 
5/21/2002 VALID ERYPOIETIN 1000 I.U. vial  rhu-ERYTHROPOIETIN AMOUN 
PHARMACEUTICAL 
INDUSTRIES Co. 
6/18/2002 VALID INSULIN H BIO R 40I.u.vial RCOMBINANT HUMAN 
INSUKIN 40 IU/ML 
SEDICO 
6/18/2002 VALID INSULIN H Bio NPH 
40I.u.vial 
RCOMBINANT HUMAN 
INSULIN (40 I.U/ML) 
/PROTAMINE-SULPHATE(0.14 
MG/ML) 
SEDICO 
2/25/2003 VALID EPOJET 4000I.u./0.4ml   RECOMBINANT HUMAN 
ERYTHROPOIETIN-ALPHA 
VACSERA 
7/30/2002 VALID CHORIONIC 5000 I.U. amp. HUMAN CHORIONIC 
GONADOTROPHIN 
AMRIYA 
7/30/2002 VALID AMRIGONE  75I.U. amp. HUMAN MENOPAUSAL 
GONADOTROPHIN (FSH+LH) 
AMRIYA 
7/30/2002 VALID FERTILINE 75 I.U. amp. FOLLITROPIN (RECOMBINANT 
FSH) 
AMRIYA 
8/20/2002 VALID ERYPOIETIN 10000 I.U. vial rhu-ERYTHROPOIETIN AMOUN 
PHARMACEUTICAL 
INDUSTRIES Co. 
10/1/2002 VALID INSULIN H MIX 40I.u./ml vial HUMAN INSULIN 
/PROTAMINE-INSULIN 
HUMAN(HUAMN INSULIN 12 
I.U/ml+PROTAMINE-INSULIN 
HUMAN 28 I.U/ml 
SEDICO 
7/30/2002 VALID CHORIONIC 1000 I.U. amp. HUMAN CHORIONIC 
GONADOTROPHIN 
AMRIYA 
4/29/2003 VALID INSULIN H BIO NPH 
100I.U.vial 
RCOMBINANT HUMAN 
INSULIN(100 I.U) &  
PROTAMINE-SULPHATE (0.35 
MG) 
SEDICO 
4/29/2003 VALID INSULIN H BIO R 100I.U.vial RCOMBINANT HUMAN 
INSULIN 100 IU/ML 
SEDICO 
4/29/2003 VALID INSULIN H MIX 100 I.U.vial RCOMBINANT HUMAN 
INSULIN(30 I.U) & 
RCOMBINANT PROTAMINE-
INSULIN HUMAN(70 I.U) 
SEDICO 
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6/3/2003 VALID REIFERON 3M.I.U. vial 
S.C/I.M injection 
 RECOMBINANT INTERFERON 
ALFA-2a 
MINA PHARM 
6/3/2003 VALID REIFERON 6M.I.U. vial 
S.C/I.M injection 
 RECOMBINANT INTERFERON 
ALFA-2a 
MINA PHARM 
9/9/2003 VALID EPOETIN SEDICO 
4000I.u./ml amp. 
ALPHA- RECOMBINANT 
HUMAN ERYTHROPOIETIN 
SEDICO 
9/9/2003 VALID EPOETIN SEDICO 
2000I.u./ml amp. 
ALPHA- RECOMBINANT 
HUMAN ERYTHROPOIETIN 
SEDICO 
11/5/2003 VALID EPOFORM 2000I.U/vial ERYTHROPOIETIN-ALPHA EIPICO-EGYPT 
11/5/2003 VALID EPOFORM 4000I.U/vial ERYTHROPOIETIN-ALPHA EIPICO-EGYPT 
7/2/2002 Valid HUMAN INSULIN -MIX 
VACSERA 30/70 40 I.U./ml 
vial 
INSULIN REGULAR HUMAN 12 
IU/ML+HUMAN  INSULIN 
ISOPHANE 28IU/ML 
VACSERA 
12/14/2004 VALID E.P.O. 2000I.U. I.V./S.C.vial  RECOMBINANT 
ERYTHROPOIETIN-ALPHA 
EL NILE. 
12/14/2004 VALID E.P.O. 3000I.U. I.V./S.C.vial  RECOMBINANT 
ERYTHROPOIETIN-ALPHA 
EL NILE. 
12/14/2004 VALID E.P.O. 4000I.U. I.V./S.C.vial  RECOMBINANT 
ERYTHROPOIETIN-ALPHA 
EL NILE. 
12/28/2004 VALID REIFERON RETARD 
160mcg/1.2ml vial 
PEGYLATED INTERFERON 
ALPHA 2 a 
MINA PHARM 
7/5/2005 VALID EPOFORM 10000I.U./ml vial ERYTHROPOIETIN-ALPHA EIPICO-EGYPT 
10/31/2006 VALID INSUNIL H NPH 100IU/ml 
vial. 
INSULIN SEDICO 
4/21/2007 VALID EPIGONAL amp. Follical stimulating hormone 
(FSH)+luteinizing hormone(LH) 
EIPICO-EGYPT 
8/14/2007 VALID FSH injection 75I.u/1 ml amp 
of lyophilized powder. 
FSH(follicle stimulating hormone) SEDICO 
4/17/2008 VALID EPIFASI 5000 I.U.amp. HUMAN CHORIONIC 
GONADOTROPHIN 
EIPICO-EGYPT 
01/04/2005 VALID HUMAN INSULIN VACSERA 
30/70 (100 I.U) 
RECOMBINANT HUMAN 
INSULIN MIX30/70(100 I.U) 
VACSERA 
7/2/2002 Valid HUMAN INSULIN VACSERA 
R 40 I.U./ml vial 
HUMAN INSULIN REGULAR  VACSERA 
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8/10/2004 VALID SOMATROPIN 4I.U./vial 
B.P.2003 
RECOMBINANT HUMAN 
GROWTH HORMONE 
SEDICO 
1/18/2007 VALID FILGRASTIN 300µg SEDICO 
LIQUID FOR INJECTION 
(RECOMBINANT HUMAN 
GRANULOCYTE COLONY 
STIMULATING FACTOR 
(FILGRASTIN) 
SEDICO 
11/23/2003 VALID ANGIKINASE 100,000 IU 
VIAL 
UROKINASE SEDICO 
11/23/2003 VALID ANGIKINASE 250,000IU 
VIAL 
UROKINASE SEDICO 
11/23/2003 VALID ANGIKINASE 500,000IU 
VIAL 
UROKINASE SEDICO 
6/18/2002 VALID SEDONASE 750,000 IU VIAL STRPTOKINASE SEDICO 
6/18/2002 VALID SEDONASE 1500,000 IU 
VIAL 
STRPTOKINASE SEDICO 
10/17/2006 VALID INSULIN H R 100 IU vial RECOMBINANT HUMAN 
INSULIN (NEUTRAL) 
SEDICO 
10/31/2006 VALID INSULIN NPH 100 IU vial RECOMBINANT HUMAN 
INSULIN 100 I.U 
VIAL+PROTAMINE SULPHATE 
0.24 mg 
SEDICO 
02/05/2006 VALID INSULIN H MIX 100 IU vial RECOMBINANT HUMAN 
INSULIN +RECOMBINANT 
PROTAMINE HUMAN INSULIN 
30IU+70 IU/ML 
SEDICO 
05/02/2006 VALID INSULIN H MIX 40 IU vial RECOMBINANT HUMAN 
INSULIN +RECOMBINANT 
PROTAMINE HUMAN INSULIN 
12 I.U+28  IU/ML VIAL 
SEDICO 
7/20/99 Valid CHORIONIC 
GONADOTROPIN 5000 
I.U(U.S.P.22) 
CHORIONIC GONADOTROPIN EL NILE. 
6/20/2000 Valid CHORIONIC 
GONADOTROPIN 1500 
I.U(U.S.P.22) 
CHORIONIC GONADOTROPIN EL NILE. 
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 Due to Biosimilars high profitability, cost, on average, 22 times as much as 
ordinary drugs (So etal, 2010) it is expected that Biosimilars will access the Egyptian 
market with a high influx rate specially after the patents for the first group of mono 
clonal antibodies (MABs) expires. That influx requires progressive policy thinking 
and well-resourced regulatory structures to properly regulate the complex 
pharmaceutical biotechnology market and at the same time ensure protection of 
public health, promote investment in local production for improving access to such 
critical medicines and creating self-sufficiency. 
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I. Problem statement 
This thesis aims to answer the question of “whether the current government 
policies for Biosimilars regulation are adequate to ensure protection of public health. 
In order to answer these question three independent variables will be examined: 1- 
The regulatory requirements and processes currently in place by the Egyptian 
government authorities involved in the process of granting market authorization to 
Biosimilars. 2- The current pricing policy and mechanisms for pricing medicines 
including biotechnology based medicines and biosimilars. 3- The current regulatory 
Intellectual Property regime post Egypt’s concession to the agreement on Trade 
Related Aspects and Intellectual property Rights (TRIPS) in relation to granting 
patents, patentability criteria and levels of exclusivity granted.  
The thesis will also examine implications of the analytical findings from the 
three independent variables (mentioned above) against the main dependent variable ( 
the role of government in protecting public health of the people. Discussions will 
touch upon implications of the current regulations on ensuring marketed biosimilar 
products are of assured quality, safety and efficacy. It will also examine if there are 
any possible loop holes in such regulatory system that may lead to regulatory failures 
such as monopolies, information asymmetries, anticompetitive behaviors or 
externalities that may require possible amendment or change in government 
regulatory interventions.   
The final chapter will set some policy options for the government to consider 
in improving the processes and bridging any gaps identified during this research. The 
research is envisaged to contribute to the scarce body of knowledge on government 
regulation in a new and critical area for the future of the healthcare sector3. This is a 
qualitative study following semi structured and in-depth interviews to generate data 
from key experts with knowledge on the subject and from different stakeholders 
including government agencies, civil society, the local and multinational 
biopharmaceutical industry. 
 
                                                            
3
 (Europe’s first guidelines to regulate biosimilars was in 2005) 
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II. Conceptual framework:  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Regulatory structures and legislative framework in 
biopharmaceuticals regulations in Egypt  
• Regulatory structures 
• Legislative framework 
• Regulatory requirements to ensure quality, safety and 
efficacy of biosimilars 
 
Egypt’s medicines pricing policy: 
• How medicine are currently 
priced 
• Different stakeholders affected 
by medicine pricing 
• Provisions of medicine pricing 
decrees in Egypt 1991,2009,2012 
 
Egypt’s Intellectual Property (IPR) law: 
• Agreement on Trade Related Intellectual Property 
Rights (TRIPS) 
• Egyptian Patent Law 82/2002 
• Role of Data Exclusivity, Free Trade Agreements 
(FTA’s) and TRIPS plus provisions in the patent law 
 
Government’s policy towards biosimilars 
in Egypt  
Pitfalls in Government regulatory Interventions fix market 
failures 
• Absence of  appropriate regulatory interventions 
to ensure quality, safety and efficacy of 
biopharmaceuticals and biosimilars in the Egyptian 
market 
• Collective action groups and their Effect on local 
production of biosimilars (pricing law) 
• Box system in registration of  biosimilars and its 
effect on information asymmetry and imperfect 
competition 
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III. Role of Government in Public Health Protection and Regulation 
of the medicines market 
Health as a public good and a basic human right will be more on the Egyptian 
political agenda as one of the main social services that the government should think 
about how to run and manage in a way that establishes the principles of social justice 
and equitable access to healthcare services. Healthcare services include healthcare 
technologies which comprise pharmaceuticals, vaccines, biological and blood 
products, laboratory, imaging and  medical devices or other technologies that 
intervene in human health and result in its improvement. Medicines are healthcare 
commodities that can immensely enhance people’s lives through its therapeutic 
value. In other words medicines can add life to years of living rather than adding 
years to life. The problem stems from the fact that medicines as healthcare 
commodities that can improve people’s life significantly have also other drawbacks 
due to its side effects. Medicines are not like clothes or chocolates they must have a 
stringent regulatory system that takes into consideration the three main aspects of 
quality, safety and efficacy in any consumer product but with special consideration to 
their risks  and tighter regulations that won’t hinder access. 
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IV. Challenges in regulating biosimilars  
The advancement in medicines and pharmaceutical technology has resulted in 
more sophisticated and complex medicines which are more selective, thus less 
harmful and more effective. Such medicines are usually produced by research and 
development based pharmaceutical conglomerates which are able to take the risk and 
finance huge R&D projects to create new molecules. The multinational 
pharmaceutical companies in order to mitigate the risk have to ensure a proper return 
of investment (ROI) in the shortest time possible. To ensure ROI, they sometimes 
price such essential products at exaggerated prices governments usually accept it 
based on the fact that they have to have the medicines readily available in their 
public health facilities. Generic medicines stem from the idea that no risk is taken in 
research and development and thus, original medicines can be copied or reengineered 
to produce cheaper identical copies. Governments all over the world, especially in 
the Middle East –and other low/middle income countries have always been pro 
buying cheaper medicines of assured quality to decrease healthcare budgets. 
Healthcare budget is already competing with other essentials such as education, food, 
security and environment which may shift money to any of these domains. The 
situation is different when it comes to medicines of complex molecules which are 
usually derived from biological origins and living organisms. The reverse 
engineering of the products is very hard (almost impossible to produce another 
identical copy) because it has other variability’s than the chemical aspects of normal 
medicines. This area is undergoing rapid advancement at an unprecedented rate due 
to its economic significance.  
In 2008, 28 percent of sales from the pharmaceutical industry’s top 100 
products came from biologics; by 2014, that share is expected to rise to 50 % ( So 
etal,2010). These medicines which are considered highly similar of original 
biological medicines are called biosimilars in this thesis it is referred to as 
biosimilars. The manufacturing process used to produce a recombinant biological 
product is much more complex than the process used for synthetic small molecule 
products.  It will usually include numerous extraction, purification and concentration 
steps that might involve protein denaturation.   Each of these steps can influence the 
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biological activity of the resultant protein (shellekens, 2004).  The properties of the 
product are highly dependent on the production process.  A producer of a biosimilar 
is clearly not in a position to replicate the manufacturing process of the innovator. In 
addition to the quality data required for all biotechnology products, the companies 
involved in the developing of biosimilar medicines must additionally submit 
“comparability data”, usually described as data from a “full comparability exercise” 
(Mellstedt,2007) .Indeed, manufacturers must characterize, in parallel, both their 
biosimilar product and the originator reference product. They must demonstrate, with 
a high degree of certainty, that the quality of the biosimilar medicine is highly similar 
to the originator/reference medicinal product. A comparability Programme is clearly 
defined and agreed upon in advance with the National Medicines Regulatory 
Authority, which defines the set of non-clinical and clinical data that are necessary to 
sufficiently demonstrate biosimilarity. (EGA, 2011). Table 4 below explains the wide 
difference in size and complexity by giving examples of three molecules Asprin, 
Human Growth Hormone and Immunoglobulin Antibody and comparing them to 
three transportation means: a Bike, a Car and a jet plane. 
Table 4: size and complexity of three medicines4 
 Small molecule 
drug 
Large molecule 
drug 
Large biologic 
Size Asprin- 
21 atoms 
hGH- 
3000 atoms 
IgG antibody- 
25,000 atoms 
Complexity Bike- 
20 lbs 
Car- 
3000 lbs 
F-16 jet- 
25,000 lbs 
(without fuel) 
 
 
                                                            
4
 http://biosimilarsource.com/biosimilars.htm 
  
23 
 
  
Figure 1: Comparison in structural complexity and size of a biological 
molecule (monoclonal antibody) and chemical molecules (Aspirin/ 
Paracetamol)5 
 
Figure 1 show a stereo-structure of two molecules on the left is a mono-colonal 
antibody (MAB) which is a biological molecule and on the right is a simple 
paracetamol (Panadol™) molecule. As both may look the same at hing sight one 
of the bumps on the MAB structure may be larger than the whole paracetamol 
molecule. The real difference in size can be shown on the left when a small 
Aspirin molecule is added beside the MAB 
 
 
 
 
 
                                                          
5
 http://www.iconplc.com/icon-files/insight-newsletter/Spring10/immunogenicity.html 
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Chapter 2: Literature Review  
I. How are Biosimilars different from Generic Medicines 
According to the European Medicines Agency (EMA): A biosimilar medicine 
is a medicine which is similar to a biological medicine that has already been 
authorized (the 'biological reference medicine').The active substance of a biosimilar 
medicine is similar to the one of the biological reference medicine. Biosimilar and 
biological reference medicines are used in general at the same dose to treat the same 
disease.). All biopharmaceuticals are inherently variable due to the fact that they are 
produced from living organisms. This variability exists within batches, from batch to 
batch, and when production processes are improved or changed or differs between 
manufacturers. The variability of biopharmaceuticals is greater than that typically 
observed for conventional pharmaceuticals and applies to originator reference 
products as well as biosimilars (EGA, 2011) 
Figure 2: Pharmaceuticals versus Biologics: Difference in classification of 
chemical based pharmaceuticals and Biological products (Biopharmaceuticals) 
  
 
 
 
 
 
 
 
 
Pharmaceutical product 
Innovator Generic 
Biological product 
Innovator Biosimilar 
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Table 3: Differential indicators for biosimilars and generics: A selection of 
indicators that are taken in to consideration to differentiate between a 
biosimilar and a generic in regulation 
 
II. Biosimilars Economic Value and role in Improving Patient’s 
Access 
Medicinal products developed through biotechnology constitute an essential 
part of medicines available to patients today and many medicines in the development 
pipeline are biotechnology products (EGA, 2011). It is inevitable that “some major 
biotechnology-derived medicines are, or will soon be, no longer protected by patents. 
As for all other medicines, when their 20-year patent expires, they will become open 
to development and manufacture by other companies. This introduces competition in 
the market which ensures continued patient access to safe, effective, and more 
affordable, biopharmaceuticals. Without competition the prices of the originator 
biopharmaceuticals would remain artificially high. Similarly, this competition will 
serve to stimulate research into new originator medicines. This fact is borne out by 
the situation in the USA where more than 80% of medicines used are generic 
medicines and where, at the same time, more new originator medicines are 
developed than anywhere else in the world” (EGA, 2011).  
 
 
 Biosimilar/follow-on 
proteins 
Generic 
Molecular complexity Complex Simple 
Manufacturing Multi-step process Simple process 
Likeness to innovator Similar Identical 
Approval pathway Abbreviated Highly abbreviated 
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To give some examples of exorbitantly high prices of branded 
biopharmaceutical products that are essential for treating diseases such as cancer and 
arthritis. A breast cancer patients' annual cost for Herceptin is $37.000. People with 
rheumatoid arthritis or Crohn's disease spend $50.000 a year on Humira. And those 
who take Cerezyme to treat Gaucher disease, a rare inherited enzyme deficiency 
spend a staggering $200.000 a year. (SO etal, 2010). Hard evidence exists on the 
economic gains resulting from interchanging originator biopharmaceutical products 
with biosimilars “The improved affordability of healthcare that could result from the 
use of biosimilar medicines is real. As an example, the EPO (Epoeitin) biosimilar 
introduction in Germany resulted in EUR 60m annual savings in the first year of the 
market. It has been estimated that biosimilars in Germany alone could contribute to 1 
billion EUR annual savings from 2017. By 2020 the savings through biosimilars 
would be more than 8 billion EUR” (EGA, 2011) 
III. Progress of Biosimilars 
The years 2013-2020 will witness many further developments in relation to 
biosimilar medicines, and healthcare professionals and healthcare purchasers need to ensure 
that they are aware of what is happening in this rapidly changing environment (EGA, 2011). 
One of the most significant new areas is the potential for the development and approval of 
biosimilar monoclonal antibodies in 2010 in Europe, 6 out of the top 10 leading 
pharmaceutical products were monoclonal antibodies. It has been estimated that worldwide 
over 45 monoclonal antibody products are marketed, with total sales in excess of $40 bln 
(Shephard,2011). The patent protection on many originator reference biotech products has 
expired already, and many more will expire over the next few years. As a result most 
commentators expect a growing number of biosimilar products on the market in the not too 
distant future. (Table. 7) presents examples of currently licensed monoclonal antibodies 
active substances with potential for biosimilar products to be developed (Emmreich,2010) 
Table 4: 10 Biological drugs to watch for patent expiry in this decade6: The table 
explains the top selling biological drugs with patent protection that is about to 
expire before 2020 
 
 
                                                            
6
 Nature Biotechnology, Volume 31 Number 4 
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Product Name Producer Patent Expiry date Sales Number of Biosimilars in 
registered or in development 
Aranesp (Darbapoetin 
Alfa) 
Amgen 2016 in EU and 2024 
in US 
2 Billion 
USD 
2  
Enbrel (Etanercept) Amgen+Pfizer 2015 in EU and 2019 
,2023,2028,2029 in 
US 
7.963 
Billion 
USD 
8 
Epogen/Eprex (Epoetin 
Alfa) 
J&J and 
Amgen 
Expired 2004 in EU 
and 2015 in US 
2.267 
Billion 
USD 
4 
Somatropin 
(Genotropin) 
Pfizer Expired 2008 in EU 
and April 2013 in US 
832 
Million 
USD 
1 
Herceptin 
(Trustazumab) 
Roche 2014 in EU and 2019 
in US  
6.317 
Billion 
USD 
7 
Humira (Adalimumab) Roche 2018 EU and 2016 US 9.265 
Billion 
USD 
4 
Neulasta 
(Pegfilgrastim) 
Amgen August and October 
2015 in EU and US 
4.092 
Billion 
USD 
4 
Neupogen (filgrastim) Amgen Expired 2006 in EU 
and  December 2013 
in US 
1.260 
Billion 
USD 
6 
Remicade (infliximab) J&J 
+Merck&Co 
2014 EU and 2018 US 8.215 
billion 
USD 
4 
Rituxa/MabThera 
(Rituximab) 
Roche 2013 in EU and 2018 
in US 
7.190 
Billion 
USD 
12 
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Table 5: Examples of currently licensed monoclonal antibodies active substances 
with potential for biosimilar products to be developed 
Trade name International 
Non 
Proprietary 
Name of 
active 
substance 
Clinical use (examples) 
Mabthera/Rituxan® Rituximab B-cell non-Hodgkin's lymphoma 
Rheumatoid arthritis 
Avastin® Bevacizumab Colorectal cancer, lung cancer 
Erbitux® Cetuximab Colorectal cancer, head and neck 
cancer 
Vectibix® Panitumumab Colorectal cancer 
Campath® Alemtuzumab B-cell chronic lymphocytic leukaemia 
(B-CLL) 
Herceptin® Trastuzumab Breast cancer 
Humira® Adalimumab Rheumatoid arthritis, Crohn's disease 
Remicade® Infliximab Rheumatoid arthritis, Crohn's disease, 
psoriasis 
Simulect® Basiliximab Transplant rejection 
Zenapax® Daclizumab Transplant rejection 
Xolair® Omalizumab Asthma 
Tysabri® Natalizumab Multiple sclerosis 
Lucentis® Ranibizumab Macular degeneration 
Synagis® Palivizumab Respiratory syncytial virus infection 
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IV. Biosimilars Regulatory Pathways: 
Regulation of biosimilars requires the interplay between several factors: Reference 
product: The product in which the biosimilar will benchmark against and on what 
basis will it be chosen. Several factors are being weighed when a regulatory pathway 
to approve biosimilars is designed. Quality: The different quality parameters 
including bioassay, characterization.  Non-clinical data: Conducting toxicological 
studies in Animals to know the toxicity profile of the product Clinical trials: the 
types of studies to know the efficacy of the product in human beings and its level of 
immunogenecity Pharmacovigilance and risk management: post-marketing studies 
to generate safety data.  Data protection: from innovator may be censored for a 
period of time after patent expiry to help regain investment and its effect on 
hampering competition from biosimilars needing to refer to innovator’s data in 
claiming similarity (Frost and Sullivan, 2013). Table 6 below explains the release 
date for a regulatory pathway or guidance issued by different National Regulatory 
Authorities on Biosimilars registration. 
Table 6: the release date for a regulatory pathway or guidance issued by 
different National Regulatory Authorities on Biosimilars registration 
 
 
 
 
 
 
Health Authority Date of guidance release 
EMA-(Europe) 2005 
WHO 2009 
MHLW (Japan) 2009 
Health Canada 2010 
Korean-FDA 2010 
US-FDA 2012 
Saudi-FDA 2012 
CDSCO (India) 2012 
EDA-(Egypt) Draft 2012 
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V. Comparison of different Regulatory pathways in EU and US: 
A. The EU approach 
The EU realized earlier than the whole word the nature of the new regulatory 
challenge with many applications for similar biologics knocking on its doors. In 2001 
they realized that the current pathway for chemical generics market authorization 
will not provide the required level of knowledge to judge the quality, safety and 
efficacy fo these products to protect safety the union’s citizens. The EU medicines 
regulations are all codified in the EU directive of 2001/83/EC. The first step was to 
demand safety and efficacy data to support the application in addtion to the 
bioequivalence studies that were conducted for generics. The process involves 
holding training workshops and consultations with the industry and stakeholders and 
was transparent. The European Medicines Agency (EMA- responsible for cross EU 
countries Market Authorization for all therapeutic products) issued a series of 
guidelines and products later to guide manufacturers on product specific issues. The 
new pathway was integrated to the 2001/83/EC directive in 2003 and applied to the 
biotech manufactured medicines and other products like Low Molecular Weight 
Heparins (LMWH)  (Bogaert, 2011). 
 
Table 7: Approved Biosimilars in Europe 
Product Name Active 
Substance 
Authorization 
Date 
Manufacturer/Company 
Name 
Abseamed Epoetin alfa 28 Aug 2007 Medice Arzneimittel 
Putter GmbH & Co KG 
Binocrit Epoetin alfa 28 Aug 2007 Sandoz GmbH 
Biograstim Filgrastim 15 Sep 2008 CT Arzneimittel GmbH 
Epoetin alfa 
Hexal 
Epoetin alfa 28 Aug 2007 Hexal AG 
Filgrastim Hexal Filgrastim 6 Feb 2009 Hexal AG 
Filgrastim 
Ratiopharm 
Filgrastim 15 Sep 2008 
Withdrawn on 
20 Apr 2011 
Ratiopharm GmbH 
Nivestim Filgrastim 8 jun 2010 Hospira UK Ltd 
Omnitrope Somatropin 12 Apr 2006 Sandoz GmbH 
Ratiograstim Filgrastim 15 Sep 2008 Ratiopharm GmbH 
Retacrit Epoetin zeta 18 Dec 2007 Hospira UK Ltd 
silapo Epoetin zeta 18 Dec 2007 Stada R & D AG 
Tevagrastim Filgrastim 15 Sep 2007 Teva Generics Gmbh 
Valtropin Somatropin 24 Apr 2006 BioPartners GmbH 
Zarzio Filgrastim 6 Feb 2009 Sandoz GmbH 
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B. The US approach:  
 
The FDA Act section 505 had two pathways : 1) 505(j) explaining 
Abbreviated New Drug Application (ANDA) which represents the regulatory 
pathway of a generic market authorization application requirements and 2) the 
pathway for follow on proteins described in section 505(b)(2) of the same act. The 
FDA approved the following follow on proteins through the FDA act: 
• Hyaluronidase recombinant human (used in several lifesaving surgical 
interventions to improve tissue epermiability)  
• Calcitonin salmon recombinant (treatment of osteoporosis) 
• Glucagon recombinant (Raises blood sugar) 
• Recombinant somatropin (Growth Hormone) 
 The US FDA approved the recombinant somatropin based on quality 
charachterization of physiochemical properties to establish that the structure and 
active ingredient are highly similar to the structure and active ingredient of the 
reference product. The manufacturer also provided “new” safety data specific to the 
biosimilar somatropin (omnitrope), vast experience and published literature and 
comparative efficacy data. In 2010, the US President signed into law a bill governing 
the regulation of biosimilars. The Biologics Price Competition and Innovation Act of 
2009 (BPCIA) permits the licensing of biological products that are shown to be 
biosimilar to previously licensed reference products.. The law nevertheless does not 
require the US (FDA) to issue any regulations or guidance to implement its 
provisions or FDA’s new authorities.  (Hordon, 2011).  
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Chapter 3: Methodology 
The general strategy for achieving the study objectives is through information 
and data collection, analyzing it and inferring some implications then providing some 
policy options that any help filling any gaps identified from the study findings. This 
area of study is seldom researched in developing countries due to various reasons the 
major of which is the lack of democratic regimes which are open for examining, 
evaluating and disseminating findings of its policies, regulations and government 
performance in any sector. Hence there is no well-established methodology that was 
revealed during the literature research on how studies of such nature are being 
conducted.  Due to the nature of information and data to be collected, being mostly 
either in drawers of government agencies or now with the digital revolution are 
sometimes on the websites, a qualitative approach is considered the most suitable 
study type. The reason is that regulations are produced as ink on paper but what is 
significant is their interpretation, implementation practices and implications of such 
regulations and policies in real life. This has to be discussed in length with experts in 
the field and other key informants who may provide insights that reveal what are the 
real practices and how it is affecting the government role to protect public interests.  
This research adopts a qualitative approach that will depend on in depth and 
semi structured interviews for data collection: interviews with key informants from: 
A-government (Ministry of Health -MoH), central administration of Pharmaceutical 
affairs (CAPA) (national regulatory authority of the government to regulate the 
medicines market),National organization for Research and Control of Biologicals 
(NORCB), the Egyptian patent office ( responsible for granting patents for 
inventions and implementing the international agreements related to Intellectual 
property protection on medical inventions), Public Procurement and tenders ( 
responsible department in the Ministry of Health which conducts the annual tender to 
procure medicines. B- Industry (biosimilars and biotechnological products 
producers) both locally manufactured and imported via local or multinational 
companies, as well as lobbying bodies such as the pharmaceutical industry chamber. 
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Desk review of Regulatory and legislative information will be collected from 
government reports and guidelines on registration of biological products in Egypt 
and other stringent regulatory authorities. Producers and industry chamber will be 
consulted on the current response to the latest pricing decree by manufacturers in 
light of the current political changes and economic depression in the country and 
how it is affecting their ability to produce and fulfill market needs of such crucial 
products. Views of producers on the role of government in promoting investment in 
development and production of biotechnology based medicines. 
In addition interviews with the representatives from the central administration 
of pharmaceutical affairs staff. The two competitor companies producing pegylated 
interferon and supplying MOH  (one multinational and other local7) will be 
conducted to validate opinions. The interviews will try to build on the current 
published literature and the analysis will feed in to the research questions on the 
ability of the government to protect public health through ensuring quality, safety 
and efficacy of biological products being granted market authorization in Egypt. It 
will also analyse the current practices of registering a biological product for the 
treatment of hepatitis C virus, versus current regulatory pathways for registration of 
Biosimilars in developed regulatory authorities (US,EU). The thesis also targets 
academic researchers and clinicians who are working in the field of researching 
treatments for hepatitis C in Egypt. This section of the thesis is not intended to 
provide a definitive judgment on any of the two pegylated interferon alfa-2 a in the 
Egyptian Market  but rather to compare the regulatory pathway both products went 
through to global best practices currently implemented in the field. 
 
 
 
 
                                                            
7
 The product (reiferon retard (Pegylated interferon alfa -2a)- later being referred to as the Egyptian 
interferon) was registered in Egypt in 2004 as a normal generic chemical medicine and not as a 
biosimilar product 
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I. Selection of interviewees: 
Selection will be based on level of expertise and understanding of the subject 
of research. The potential to provide valuable data that may not be in public domain 
and discuss openly sensitive issues as well as shed insights on implications. Since 
this research is focused on government regulation of the private sector the key 
informants to be interviewed will be from government and industry as well as some 
civil society representatives who act as a watch dog and or independent researchers 
or academics. 
II. Recruitment strategy:  
A list of expert individuals on the subject with the above knowledge was 
created using several public sources (professional networking websites as LinkedIn, 
and literature research). In addition the Principal Investigator has working relations 
with some governmental organizations who may have some of the required key 
informants. The principal investigator also participated in an event organized by the 
central administration of pharmaceutical affairs, registration of biological products 
section and which gathered industry interested to produce or import biosimilar 
products in Egypt. The 2 days feedback workshop was aimed at gaining the 
industry’s view points and feedback on the draft guidelines for registration of 
biosimilar products in Egypt. This was a great opportunity to observe the 
deliberations between industry and government on the draft regulatory and technical 
requirements proposed. It was also a very good chance to network and establish 
contacts with both regulators and industry for the research. 
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III. Sampling: 
The issue of sampling in qualitative research has major debates concerning 
what is the right sample size. One factor which is significant in qualitative data 
collection is saturation. In a qualitative framework, research based on interviews 
often seeks to penetrate social life beyond appearance and manifest meanings. This 
requires the researcher to be immersed in the research field, to establish continuing, 
fruitful relationships with respondents and through theoretical contemplation to 
address the research problem in depth. Therefore a small number of cases (less than 
20, say) will facilitate the researcher’s close association with the respondents, and 
enhance the validity of fine-grained, in-depth inquiry in naturalistic (real life) 
settings (Crouch etal, 2006). Guest, Bunce, and Johnson found with their study that 
involved 60 interviews theme saturation was achieved after 12 interviews (Guest 
etal, 2006). The domain studied also is another factor to affect the sample size. In a 
recent research study by Baker and Edwards of how many qualitative interviews are 
enough it is mentioned that although many experts agree that saturation is ideal, 
some give numerical guidance. For example, Adler and Adler advise graduate 
students to sample between 12 and 60, with 30 being the mean; and Ragin suggests 
that a glib answer is ‘20 for an M.A.  thesis and 50 for a Ph.D. dissertation’ (Baker, 
S., & Edwards, R. (n.d)). In my research I used purposive non probability sampling 
which gives the researcher the chance to choose the sample that best fulfills the 
objectives and need of the research.  A sample size of 31 key experts in regulation of 
the biopharmaceutical sector as well as producers, importers and other stakeholders 
was aimed at and achieved 55% of which due to various constraints explained in the 
study limitations section. Number of key informants per section was designed based 
on the below criteria: 
1- At least 10 years of knowledge in medicines regulation and 3-5 
years of which in regulation of biologicals in Egypt 
2- At least 10 years of experience in pharmaceutical industry with at 
least 3-5 years in biopharmaceutical research and development, 
production, marketing, safety and efficacy 
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3- At least 15 years’ experience in policy making position in medicines 
regulation including procurement and pricing policies 
4- At least 20 years of experience in clinical research / practice in 
treatment of hepatitis C and liver diseases in Egypt 
5- At least 7 years of experience in patent examination and negotiation 
of Intellectual property Rights agreements at national and 
international level 
IV. Interviews process:  
Introductory email messages were sent introducing the Principal Investigator 
and explaining in brief the research objectives and outcomes. IRB consent forms 
were attached along with the questionnaire tool. The message included an invitation 
to be part of the research project and another invitation for discussing any questions 
or concerns they might have before enrolling in the interview process as explained in 
the IRB form. A total of 31 attempts was done to conduct the interviews resulted in 
17 interviews. All interviews were pre appointed and lasted between 45 minutes to 
several hours. Interviews were either conducted through a field visit to the 
government agency concerned or by telephone. 
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Table 8: Interviews attempted and conducted 
 
 
Number of 
interviewees 
attempted 
Number of 
interviewees 
done 
Ministry of Health- Procurement of Medicines Department 1 1 
Central Administration of Pharmaceutical Affair(CAPA)- inspection 
department of biologicals 
1 1 
Central Administration of Pharmaceutical Affairs - biological 
registration department 
3 1 
Egyptian pharmacovigilance center 1 1 
Technical office of the Asst. Minister of Health of Pharmaceutical 
Affairs 
3 1 
Independent –Senior ex-CAPA 1 1 
Rhein-Mina Pharm 2 1 
Roche 3 1 
Other potential producers or importers 3 1 
Pharmaceutical Industry Chamber 2 2 
Civil Society (patient’s rights) 1 1 
Key Opinion Leader Clinicians using interferon in treating patients 
with hepatitis C Virus 
4 2 
Military hospitals 2 0 
Egyptian Patent Office/Academy for Scientific Research 3 3 
Total 31 17 
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V. Development of the questionnaire tool 
A master questionnaire tool was developed including 40 questions divided on 
two sections by interviewee’s type. 1) Questions for Government, 2) Questions for 
Industry and private sector. Questions under each of the above section were 
distributed against sub sections of the three main independent variables in question: 
a) Requirements for quality, safety and efficacy of biosimilar products b) New 
pricing policy and pricing mechanisms and its relation to availability of biosimilar 
products c) Intellectual property regime and its relation to access to biosimilar 
products. I also created another set of subsections representing the dependent 
variables which I am assuming will be affected by the 3 independent variables , this 
included open ended questions and in-depth discussions on :  i) opinion of the Key 
Experts on role of government in public health protection based on the current 
regulations ii) opinion of the Key Experts on any possible market failures 
(externalities, information asymmetry, collective action, lack of transparency, 
anticompetitive behavior) and iii) opinion on the role of government in promoting 
investment in development and local production of biopharmaceuticals.  
I wanted to challenge their answers against possible implications that I 
propose based on what they answered on the independent variables questions set. 
This helped to validate answers, clarify any misunderstandings between the 
interviewer and interviewee and to add valuable informed expert’s opinion to my 
discussion chapter. Qualitative data were collected through the semi structured and 
in-depth interviews using questions from the questionnaire tool.  Due to the nature of 
the topic the data collected was more focused on the philosophy behind the 
regulations in place, how it compares to global regulations and regulations in 
stringent regulatory authorities.  It also took the form of insights trying to assume 
positive and negative implications of the current regulations to public health in Egypt 
and possible loop holes in the regulatory system which may create market failures. 
The interviewer took notes either on electronic or manual notepads and transcribed 
after the interview. 
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VI. Direct limitations for this type of research: 
Government or powerful groups (nondemocratic society) restrict free 
inquiries and keep research limited to safe topics forced to support official 
Government policies and shy away from politically sensitive topics. Study 
limitations: 
1. I wasn’t able to select a randomization sampling technique due to 
the nature of the topic requiring specific degree of knowledge and 
expertise, thus this study findings can’t be generalized and it doesn’t 
aim to do that. 
 
2. Possible bias from the PI due to prior knowledge of the subject and 
preconception on the positions of some key experts on the subject 
due to working relations with some of them. 
 
 
3. Due to the political and commercial sensitivity of the subject and the 
data asymmetry being mostly not in the public domain and within 
closed doors and a lot of gate keepers who control access to the 
information, data limitations may occur.  
 
4. Some Government officials may have secrecy attitude and fear that 
infringing their confidentiality may result in negative drawbacks on 
their careers, especially with the current political turmoil in Egypt.  
 
 
5. Commercial producers may feel awkward that an external researcher 
is tackling issues related to one of their products and that results if 
published may affect their business, they may become reluctant to 
participate. 
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6. Breaking the culture of closed doors in governmental intuitions and 
specially the Ministry of Health is a challenge, being responsible for 
a social sector that may create and upheaval of public discourse if 
threatened. Although made clear during my introductory emails that 
this research is done in my personal capacity as a postgraduate 
student in the school of Global Affairs and Public Policy at the 
American University in Cairo and that this research doesn’t have 
any relation to my current professional employer. Being an 
employee of one of the United Nations agencies working on public 
health, tackling an issue that is relatively new globally and that 
affects a significant portion of medicines for diseases with high 
mortality and morbidity burdens and with no current official 
regulations in Egypt, created skepticism and resistance among some 
employees in the biological registration section leading to inability 
of interviewing some of them despite several attempts.  
 
7. Due to time constraints and the scarcity of key experts who fulfill 
the above criteria and their very busy schedules made it hard to 
always find the right time to do the interview face to face and led to 
conducting the interview over-phone.  
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VII. How to solve data limitation problems: 
Some of the above limitations are unsolvable like 1 and 2. For the rest two 
main strategies were utilized. The first one is to make the interviewee at ease and 
explain in depth and transparency the situation with all possible use of the data in the 
future yet with focus on the confidentiality and protection of the identity of the 
interviewee. The second solution needed was to find replacements for key 
interviewees who refused, were reluctant, resisted or shied away from speaking. To 
solve this I targeted key experts who have been in the same department and moved to 
another department, left the government recently or retired and thus have no problem 
in speaking freely and openly, I also tried to be cognizant about possible bias in 
experts opinions due to internal politics.  
VIII. Possible use of resulting findings: 
Based on the data collected on the three independent variables the question 
on whether the current regulatory policy towards Biosimilars is adequate to ensure 
public health protection. The analysis will then try to draw conclusions and 
recommend some policy options to the government for improvement of the current 
regulatory system for biopharmaceutical sector in Egypt. 
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Chapter 4: Data Analysis   
I. The Regulatory Structure for Biosimilars in Egypt: 
The world Health Organization conducted a regulatory authority assessment 
in 2008 which resulted in a report of recommendations to establish an independent 
autonomous or semi-autonomous regulatory authority in Egypt to regulate the 
medicines market. The Egyptian Drug Authority (EDA) was established by the 
Assistant Minister for Pharmaceutical affairs assigned by the prime minister’s decree 
number 4094 for the year 2008 was a landmark towards restructuring of the 
regulatory framework for medicines in Egypt. The main aim of establishing the 
authority was to create an independent body with clear structures and responsibilities 
that follows standards of the stringent regulatory authorities (US FDA, Canada, 
Australia, Japan and European Medicines Agency). However the authority remained 
under the Ministry of Health and with no financial or structural independence. Three 
main bodies stems from the EDA, namely the Central Administration of 
Pharmaceutical Affairs (CAPA), the National organization for Research and Control 
of Biologicals and the National Organization for Drug Control and Research 
(NODCAR)8. 
 
Figure 3: The Egyptian Drug Authority 
Photo credits to EDA website (www.eda.mohp.gov.eg) 
                                                            
8
 Responsible for chemical based medicines thus outside the scope of this research and will not be 
tackled 
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A. The Egyptian Drug Authority (EDA) is the pharmaceutical regulatory body of 
the Egyptian Ministry of Health (MOH) and it is responsible for: 
 Protecting people's health by regulating safety and quality of pharmaceutical 
products. 
 Regulation & legislation of pharmacy practice. 
 Availability of high quality medicines at affordable prices. (EDA, 2009). 
B. The Central Administration of Pharmaceutical Affairs (CAPA): 
 
CAPA is a regulatory body that carries out a range of assessment and 
monitoring activities for human and veterinary medicines, food supplements, 
insecticides, medical devices & cosmetics to ensure that they are of an acceptable 
standard with the aim of ensuring that the community has access to safe , effective 
affordable & secure products(EDA,2009).  
 
 
Figure 4: organizational structure of (CAPA) 
Photo credits to EDA website (www.eda.mohp.gov.eg) 
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C. The National organization for Research and Control of Biologicals (NORCB) 
 
The main function of NORCB is to ensure the safety, quality and efficacy of 
all imported and domestic Biologicals in Compliance with WHO requirements & 
international organization for standardization. One department is in the scope of this 
research the General Administration for Technical Affairs - clinical trials and lot 
release. (EDA, 2009). 
The National Organization for Research and Control of Biologicals was 
established in 1995, according to Presidential Decree No. 398/1995, for ensuring 
Safety, Quality and Efficacy of all used Biological products and Vaccines (locally 
produced or imported). In 2006, The Ministerial Decrees No. 262/2006 & 
No.263/2006 were issued to implement the Presidential Decree No. 398/1995, the 
Board of directors and chairman of NORCB were assigned. The Quality 
Management System was certified by TUV according to ISO 9001/2000 in October 
2008, according to ISO 9001/2008 in January 2010. Three labs of the Organization 
were accredited by the EGAC according to ISO/IEC 17025/2005 in September 2010. 
Finally the organization recognized by WHO in October 2010 as a functional 
National Regulatory Authority (NORCB, 2011).  
 
 
Figure 5: Organizational structure (NORCB)  
Photo credits to EDA website(www.eda.mohp.gov.eg) 
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D. The Egyptian Pharmacovigilance Center (EPVC): 
 
 
Figure 6: Organizational Structure of the Egyptian Pharmacovigilance Center 
Photo credits to EPVC website (www.epvc.mohp.gov.eg) 
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The center was established by a special decree from the 2008 formed position 
of Assistant Minister of Pharmaceutical affairs. The decree number 2 for the year 
2010 (2/2010)9 is applied to both pharmaceutical and biological products and is 
based on several decrees, the most relevant of which is decree number 397 for the 
year 1995 related to the establishment of a National Center for Adverse Drug 
Reactions Monitoring in Egypt. The decree clearly outlines in 11 articles the roles 
and responsibilities of the government and market authorization holders (MAH) of 
pharmaceutical or biological products to ensure safety of the products post 
marketing. It creates the new responsibility of the government to monitor, analyze, 
assess and take suitable action based on reported adverse events of medicines. 
Marketing Authorization Holders (MAH) are committed to report in a maximum of 
15 days any serious adverse drug reactions resulting from the use of their products to 
the (CAPA). The MAH should report periodic safety update reports (PSURs) or any 
phase 4 clinical trial (post marketing studies) data to CAPA. Article 5 in the decree 
stats that PSUR’s submission is required at the time of re-registration of the 
biosimilar product or generic product, and at the time of registration and re-
registration for the innovator. The EPVC is entitled to receive any Individual Case 
Safety Reports (ICSR) about adverse drug events from healthcare professionals 
(doctors, nurses, pharmacists, etc…), patients or their relatives or any other person 
for analysis, assessment and entry to the national adverse drug events database. 
Article 7 of the decree put the responsibility of reporting any Suspected Unexpected 
Serious Adverse Reactions (SUSARs) which may threat the life of any volunteer or 
patient involved in a clinical trial  taking place in Egypt on the MAH or Principal 
Investigator (PI) within 1 day, while other to be submitted within 7 days from 
happening. Article 8 clarifies the authority of the EPVC to raise a report with its 
recommendations to the technical committee at CAPA to take any of the following 
actions: 1) ban importation, 2) ban marketing, 3) suspend marketing and stop 
manufacturing for a limited duration. 
                                                            
9http://www.eda.mohealth.gov.eg/Download/English%20Decree%20for%20the%20assisstant%20min
ister.pdf (Amended in 2012 to decree 368 for the year 2012 (368/2012) with no major changes to the 
center’s mandate ) - 
http://www.epvc.gov.eg/NewsAttachments/%D9%82%D8%B1%D8%A7%D8%B1%20%D9%88%D
8%B2%D8%A7%D8%B1%D9%89%20%D8%A8%D8%B4%D8%A3%D9%86%20%D9%85%D8
%B1%D9%83%D8%B2%20%D8%A7%D9%84%D9%8A%D9%82%D8%B8%D8%A9%20%D8%
A7%D9%84%D9%85%D8%B5%D8%B1%D9%89%204-7-2012.pdf 
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II. The legal framework: 
During the interviews it was clear that in Egypt the culture of governmental 
institutions in functioning is speaking to each other by reference to laws and 
ministerial decrees. A law would give the regulation a relatively strong power, a 
ministerial decree has the enforcement power of  a law but can always be challenged 
and changed with another decree without going back to the parliament; a presidential 
decree is similar to the ministerial decree but with more powers in terms of 
implementation and continuity .  In Egypt regulation of biopharmaceuticals was first 
mandated in 2009 using the Ministerial decree 297/2009 (for the year 2009). The 
decree established the rule, procedure for registration of biological products, 
vaccines, serums and blood derivatives10. This decree sat the guidelines on what is 
required from manufacturers and importers of biopharmaceuticals to register a 
biopharmaceutical product in Egypt. Requirements included technical data to present 
for quality, safety and efficacy as well as other administrative forms to complete or 
provide about the company and the product in need for registration. However in 
order to implement such decree functional regulatory structures have to be in place 
with clear mandate and rights. The two administrative decrees “complementing the 
ministerial decree” number 3 and 16 for the year 2009 filled this gap by setting the 
administrative rules for establishing the biological products inspection department 
and the biological products registration department respectively. This was followed 
by the presidential decree 244/2009 to iterate the executive functions for the National 
Organization for Regulation and Control of Biological products (NORCB). The 
NORCB was established in 1995 by the presidential decree 398 however with no 
clearly iterated executive functions. NORCB act as the technical arm for the 
registration department of biological in the Central Administration for 
Pharmaceutical Affairs (CAPA).  
 
 
 
                                                            
10
 Vaccines, serums and blood derivatives regulations are outside the scope of this research 
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III. The regulatory procedure:  
A. Procedure prior to the 2009 ministerial decree:  
Prior to the 2009 ministerial decree which regulates the registration of 
biological products the requirements for registration of biological products were 
similar to chemical based medicines. In that sense the requirement for a chemical 
based generic medicine was to provide proof of quality and for safety and efficacy to 
rely on the safety and efficacy data from the originator or brand product. In 2008 an 
amendment which required a proof of therapeutic equivalence to be provided in the 
generic product’s dossier to ensure the efficacy of the generic is within an acceptable 
range to the originator. Usually between 80-125% of the Area under the curve 
(AUC) in most guidelines and differs in case the product is of low therapeutic index 
meaning high toxicity probability, ranges between 95%-115%. 
B. Procedure post the 297/200911 ministerial decree:  
This decree differentiated between registration requirements of biological 
products and chemical based medicines. The decree set the technical requirements of 
quality, safety and efficacy requirements for both original products and similar 
biological products. The requirements requested a full dossier data including quality 
with all the chemistry manufacturing and control data, pre-clinical (toxicological 
safety studies testing the product in animals) and finally clinical studies to proof 
efficacy. These guidelines didn’t differentiate between original and similar biological 
products and asked for a complete dossier with full quality, non-clinical and clinical 
data without explicitly differentiating between reference biological products and 
biosimilars. The guidelines to interpret this decree have differentiated though 
between the requirements for locally produced and imported products. Difference 
however was mainly in administrative requirements for example with the imported 
products they needed the certificate of pharmaceutical product (CPP) which means 
that this product is circulating freely in the market of its country of origin or any of 
the reference countries to Egypt . For locally manufactured products there was a need 
for the reports of the inspection department on Good Manufacturing Practice while 
                                                            
11
 http://www.eda.mohealth.gov.eg/Download/Docs/English_version.PDF 
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for the imported products if they produced in a reference country then the Egyptian 
authorities doesn’t inspect the facility and they accept the decision of the local 
authorities in the country of origin. 
IV. Requirements to ensure Quality Safety and Efficacy of Biosimilars 
in the Egyptian Market  
A. Biological products:  
According to the WHO Technical Report Series, No. 858, 1995, a  Biological 
products are defined as medicinal products made of substances extracted from or 
produced by living sources whether they are genetically modified living organisms or 
liquids and tissues extracted from various human or animal sources (WHO 
TRS,1995) (EDA,2010). Various types of biological therapeutic products exist: 
1. Immunological medicinal products: Any medicinal product consisting of 
vaccines, toxins, serums or allergen products 
2. Medicinal products derived from human blood and human plasma 
3. Medicinal products developed by means of biotechnological processes 
(Biopharmaceuticals): Recombinant DNA technology: Controlled expression of 
genes coding for biologically active proteins in prokaryotes and eukaryotes 
including transformed mammalian cell. 
All the above categories are common in that they are more difficult to 
characterize or control than chemically synthesized pharmaceuticals due to their 
complex molecular structure (EDA,2009 ). 
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Figure 7: Recombinant(r) DNA process for generating biopharmaceutical 
proteins 
Photo credits: (fhs-bio-wiki.pbworks.com) 
B.  Biosimilar product: 
 
A biological product (other than blood derived products, recombinant analogues, 
vaccines and sera) having the same active substance, dosage form, strength and route 
of administration of a reference biological product and has proven through (a 
comparability process) that its quality, safety and efficacy are highly similar to a 
reference biological product when prescribed in a claimed indication. This means 
that for every biosimilar product claimed there is a reference product. In order for a 
biosimilar product to claim similarity to a reference product the registration dossier 
has to include a quality comparability exercise in addition to reduced pre-clinical and 
clinical comparability studies. The reference product has to be marketed in Egypt or 
has been marketed for at least 4 years (well established) in the markets of any of the 
reference countries for Egypt (mainly Western Europe, USA, Canada, Australia and 
Japan). One reference product will be used for the three types of comparability 
(quality, pre-clinical and clinical). Figure 8 below illustrates how much data need to 
be generated for demonstrating quality, safety and efficacy of a biosimilar versus a 
stand-alone or an innovator (reference) product while Table 9: illustrates the data 
required to be submitted by a company to apply for a registration license for its 
product type (Innovator , chemical Generic, biosimilar)12.  
 
 
                                                          
12
 PowerPoint presentation by the biological registration department – CAPA – Feedback workshop on 
draft guidelines for biosimilars registration in Egypt 24-5 February 2013, Cairo, Egypt. 
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Figure 8: Registration data required for - Biosimilar (left) and originator or 
Standalone13 (right) 
 
Table 9: Registration data required for innovator, generic and a biosimilar 
Regulatory 
attribute 
Type of product 
Innovator Generic Biosimilar 
Quality Full quality dossier Full quality 
 dossier 
Full quality dossier plus 
Comparability exercise 
Non-clinical Full non-clinical 
Dossier 
No data 
Required 
Comparative in vitro studies 
Comparative PK and/or PK/PD 
Comparative repeat-dose 
Toxicity, other studies.  
 
Clinical Full clinical dossier 
Data from Phase I, II and III 
studies 
BE study Comparative Phase I (PK/PD) 
And Phase III ( Safety and 
Efficacy) Studies 
                                                          
13
 Are new molecular entities from the same class of the original product yet doesn’t claim similarity. 
clinical
pre clinical 
(toxicology 
studies)
Quality 
+Comparability
clinical
pre clinical
(toxicology 
studies)
Quality (CMC)
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C. Quality data (Chemistry, Manufacturing and Controls - CMC) :  
The biosimilar approach require complete quality data including data on 
analytical techniques methods used in analysis and their validation, results of 
analysis, for the raw material (active substance), inactive substances (additional 
material with no therapeutic value) and finished product (final product) in addition 
manufacturing process in step wise presentation, in process controls and stability 
data for both active and finished product. In addition to that data on packaging 
materials used has to be included. The comparative characterization studies This is 
the basic concept which needs to be established prior to moving to the non-
clinical/pre-clinical and the clinical studies. In this comparative exercise analytical 
validated methods should be used to characterize the following in both the biosimilar 
and the reference product: 1- physiochemical properties, 2-impurity and 
contamination, 3- structural characterization and 4-biological action assays. 
D. Pre-clinical data (toxicology studies in animals): 
The most important factor in these studies is the repeat dose toxicity studies at least 
one study of long duration with toxico- kinetic measurements taken should be 
conducted. 
E.  The Antigenicity / Immunogenicity:  
Means the possibility of the medicine inducing antigenic response in the 
patient, leading its immune system to produce a reaction (antibodies) against its own 
body which may lead to death in a very short interval. This is actually one of the 
main differences between biological and chemical medicines and considered 
significant factor in granting market authorization to a biosimilar product. Although 
animal immunogentic studies may not accurately predict immune response in 
humans, antibody measurement can be a clear factor in determining immunogenicity 
and should be included in the repeat dose toxicity study. Other studies may include 
the following: Single-Dose Toxicity, Repeat-Dose Toxicity, Genotoxicity, 
Carcinogenicity, Reproductive and Developmental Toxicity, Local Tolerance 
Fertility and Embryonic Development, Embryo-Fetal Development, Pre- and Post-
natal Development & Maternal Function, Offspring, Juvenile, Second & Third-
Generation Studies, Local Tolerance.  
  
53 
 
F. Clinical data (comparability head to head clinical studies)14: 
The clinical comparability exercise is a step wise procedure it starts with studies to 
know the effect of the body on the ingested biosimilar (pharmacokinetic studies -PK), 
studies to determine the effect of the biosimilar on some biomarkers 
(pharmacodynamics studies - PD) then it move to the efficacy trials and finally  
clinical safety trials (safety in humans).  
 PK studies: Absorption, Distribution, Metabolism and Elimination (ADME) are 
the main parameters for investigation. A range of acceptance for each parameter 
demonstrating similarity versus the reference product should be pre-determined 
by the manufacturer, justified and documented in the study protocol. Due to the 
lack in acceptance criteria for biological in the literature. The acceptance range 
for chemical based medicines of 80%-125% may be applied. 
 PD studies: specific markers in the body should be selected and monitored for 
the effect of the reference and biosimilar products. PD markers like reticulocyte 
count in case of erythropoietin for example can be used as substitute for clinical 
effectiveness if therapy induced changes can affect clinical outcomes. 
 Efficacy trials:  preferably double blinded or at least observer blind. 
 Clinical safety: pre-market authorization data should be obtained from an 
adequate number of patients to provide a comprehensive safety profile. Adverse 
events observed if any should be compared in terms of type, severity, and 
frequency. The focus should be on immunogenicity data and it is essential to do 
a pre and post marketing immunogenicity studies.  
 Risk Management (RMP) and Product Pharmacovigilance Plan: should be 
presented to the Egyptian pharmacovigilance Center. It should include post 
marketing immunogenicity study at the time of submission of the market 
authorization application. If at any of the above steps significant difference 
between the biosimilar product and the reference product are detected, this 
should be investigated and if there is no justification for such differences not 
related to the product’s performance of quality, safety and efficacy the product 
may not be accepted as a biosimilar and a Standalone (asks for full product 
                                                            
14
 Power point presentation by Dr Heba Khalil , NORCB on clinical requirements for Biosimilars 
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quality, safety and efficacy data not in comparison to a reference product) 
application may be considered. 
V. Procedure suggested in draft guidelines for biosimilar registration in 
Egypt 2013: 
Two regulatory pathways can be adopted for registration of biosimilars inn 
Egypt: 
A. The Final dossier pathway:  
This is for finished biosimilar products imported in its finished form or for a 
biosimilar product that is developed, manufactured, and filled under the control of 
the regulatory authority of the country of origin and only labeling and secondary 
packaging takes place in Egypt15. In this case the dossier for the finished product 
only is assessed in Egypt. Figures 9 and 10 explains the step wise regulatory pathway 
which an imported and a locally manufactured biosimilar pass through to gain  
registration license  in Egypt according to the latest draft biosimilar guidelines issued 
by CAPA biological registration section. 
 
  
                                                            
15
 placing the vial or main product container in to the cartoon box “secondary package” 
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Figure 9: Imported biosimilar regulatory pathway in Egypt 
 
 
Technical Evaluation occurs side by side 
Phase III (technical evaluation)
Results in 60 working days
The importer 
submits the 
complete 
dossier to 
the 
concerned 
authorities 
for 
evaluation
The different 
sections of the 
dossier goes to 
different 
regulatory 
structures
Module 2 which includes 
summary of the quality, 
safety and efficacy 
results of the biosimilar 
product goes to the 
Biological registration 
section which conduct a 
review and send to the 
Biologicals evaluation 
technical advisory 
committee in the 
Central Administration 
for Pharmaceutical 
Affairs (CAPA)
Module 3,4,5 of the 
dossier which 
includes the 
detailed results of 
the quality (M3), 
Safety (M4) and 
Efficacy (M5) goes 
to the technical 
affairs department 
in the National 
Organization for 
Drug Control and 
Biologicals (NORCB)
The Site Master 
File (SMF) , the 
Master 
Production Plan 
and the 
validation 
documents of 
the different 
processes 
involved in the 
production of 
the biosimilar 
product goes to 
the Biologicals 
inspection 
department in 
CAPA
The stability 
studies goes 
to the 
stability  
technical 
advisory 
committee 
in CAPA
The Risk 
Manageme
nt Plan 
(RMP) and 
Public 
Safety 
Update 
Reports 
(PSURs) 
goes to the 
Egyptian 
Pharmacovi
gilance  
Center 
(EPVC)
Phase II (Pricing)
Decision in 60 working Days
The importer fills all the forms and and provides 
all the documents that justifies the price he is 
asking fo rthe product according to the current 
Law 499/2012 
The application for pricing is 
investigated and the advisory 
committee for pricing 
provides its decision
If the price is satisfactory it continues to
Phase III , if the price is not satisfactor the 
manufacturer can appeal or 
stop the registration plan
Phase I (Box Inquiry)
Decision in 15 working days 
importer sends an inquiry if the Box is open 
for this type of products or not
If yes he moves to phase 2 
if no he will wait until a place is free
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B. A stepwise pathway:  
This is pertaining to biosimilar products developed and manufactured in 
Egypt or in the case of a manufacturer importing the final product in the form of bulk 
and doing the primary packaging (adding the injection powder or solution in to the 
glass vial). In this case the development and registration process goes in parallel.  
The box approval and the pricing steps are cross cutting with the final dossier 
procedure mentioned above. However it should be noted that for the Box approval to 
be granted there has to be less than 12 similar products of the production in question. 
6 of which are imported and 6 are locally produced. So in case the product is locally 
produced and the 6 slots for locally produced products are filled the company has to 
park its product application on a waiting list until a slot is available and can’t  
compete for the slots of the imported products and vice versa. 
In the production of biological products the product is the process and hence 
the Egyptian regulatory authority has to evaluate the different phases of development 
and manufacturing in a step wise approach to ensure the product is being 
manufactured according to Good Manufacturing Practices and to ensure its process 
will render a product with high probability to produce acceptable results when it 
undergoes the comparability studies in quality, safety and efficacy. The regulatory 
pathway for the locally produced biosimilars post the box and pricing phases: 
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Figure 10: Proposed regulatory pathway for a locally manufactured biosimilar 
in Egypt16 
 
 
 
 
 
 
 
 
 
 
                                                          
16
 Phase 1 and 2 are the same as the imported biosimilars pathway hence omitted for layout issues 
During the 3 years preliminary approval 
Phase 4 and 5 has to be completed  
• Evaluation of the 
Site Master File 
for the API 
producer
• If accepted a 3 
years 
preliminary 
approval to 
manufacture the 
finished product 
, perform the 
stability studies
• toxicology 
studies is 
granted
Phase 3 
(Active 
Pharmaceuti
cal 
Ingredient 
Evaluation)
• In 3 years time conduct and submit 
the following
• Submitting the stability study data for 
the stability committee in CAPA
• the analytical procedures and pre 
clinical study results and the clinical 
studies protocol  for the NORCB and 
ethics committee in MOH
• Submit the Master Production Plan 
and process validation to the 
biological inspection department in 
CAPA
• Clinical studies  performance
Phase 4 
(Quality,Stability, 
pre-linical studies 
and clinical 
protocol) 
submission
• Evaluation of 
Clinical studies in 
NORCB
• Evaluation fo the 
Risk 
Management 
Plan (RMP) in 
EPVC
Phase 5 (complete 
dossier with approved 
stability, analytical 
reports, pre clinical 
and clinical studies as 
well as the Risk 
Management Plan 
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C. Issuing a market authorization (registration) license:  
 
Reports from the different working parties involved in phase III technical 
evaluation (CAPA, NORCB and EPVC) are presented to the technical advisory 
committee on biological registration and a decision is made within 60 working days 
based on the results of whether to grant or refuse the marketing authorization. The 
total duration expected for granting or rejecting a marketing authorization request for 
an imported biosimilar product is 39 weeks and for a locally manufactured product 
excluding on how much time the manufacturer will use from the 3 years grace period 
given to conduct all the quality, safety and efficacy studies 52 weeks. The final stage 
is the re-registration when the company reapplies for its expired market authorization 
in 10 years. 
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VI. The pricing policy and pricing mechanisms 
Medicine pricing is an essential element of medicines regulatory policy. As it 
was explained in the different regulatory pathways for biosimilars, pricing agreement 
comes before technical evaluation which gives a strong perception of it being a “rate 
limiting step” that affects if the product will continue in its registration process or it 
will stop. Pricing becomes even important when it comes to biological products of 
sometimes sophisticated biotechnology industrial development techniques and of 
high risk of unpredictable behavior of the product due to its origin coming from a 
living organism and complex structure.  Biologicals are often of higher price tier than 
chemical medicines due to the above mentioned reasons but also due to the fact that 
many of them are treating either complex disease, orphan diseases or are lifesaving 
products. Since the pricing issue is often charged with push and pull and exercising 
of pressure tools between the government and the company. Biosimilars coming to 
governments as a safe haven to reduce costs of sometimes exorbitantly expensive 
branded biological, especially now with the Egyptian government planning to 
implement universal health coverage and designing their health services package 
which will be covered under the mandatory social or tax based insurance scheme17.  
Based on epidemiological studies, essential medicines for diseases that affect 
the majority of the population would presumably include a lot of biological and 
potentially biosimilars in the upcoming years. Egypt has some of the highest rates for 
several types of cancers globally amongst are the breast cancer, hepatitis C which 
can progress to develop liver cancer, diabetes. All of these are treated with medicines 
from biological origin; such medicines are expected to be purchased in the package 
for reimbursable health services under the new health insurance law. Tackling how 
medicines at large are priced in Egypt would give a proxy indicator of how products 
of relatively higher price tier may be affected in terms of patient’s access to these 
products. The government of Egypt set the rules and procedures for pricing 
medicines for human use and based on such procedure the company and the pricing 
committee undergoes the negotiation process to reach an agreement on what may be 
a fair price.  
                                                            
17
 Presentation by Dr. Mohamed Moustafa Minister of Health and Population , Sharm EL Sheikh, April 2013 
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VII. Pricing regulatory structures: 
A. The pricing committee at CAPA: 
The main regulatory structure in place is the pricing committee which is 
responsible for reviewing the pricing application and documents provided by the 
manufacturer. The pricing committee is composed of seven representatives , three 
from: The Ministry of health (focus on therapeutic return or value to patients), The 
ministry of trade (focus on industrial development) and The ministry of supplies 
(focus on achieving lowest possible price). In addition some university professors 
from different technical backgrounds in the pharmaceutical field for any 
consultations related to the therapeutic value of such products. The selection of the 
committee members is not based on clear publically available criteria and is assigned 
by the head of the CAPA. Decisions made by the pricing committee shall be 
endorsed by the Minister of Health. 
 
VIII. Legal framework for pricing in Egypt 
A. Ministerial Decree 314/1991:  
This was the first decree that clarified the way medicines are being priced and 
the different price components. It used the cost plus pricing mechanism. The cost 
plus mechanism that used to be in place depended on a fixed profit margin on local 
and imported products that the governments assigns and is added to the total the 
company declares as costs of developing the product until it is ready for sale to the 
first point in the supply chain. Due to various disadvantages of such system including 
claims that the invoices presented by the companies to justify the total costs are 
unverifiable and hence presents a window for maximizing profits based on false 
invoices. The process was also claimed to be cumbersome and consuming for both 
the manufacturer who tries to collect invoices for every expense used in producing 
and marketing the product and also for the assessor who faces a huge pile of 
documents to go through and verify within a limited time frame. 
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B. The pre-revolution pricing decree (373/2009):  
 
The decree number 373/2009 was issued in 2009 by the Minister Hatem El 
Gabaly. The decree shifted the way medicines has been priced in Egypt from “cost 
plus” to a new mechanism known as reference pricing or “external” reference 
pricing.  The main idea of the reference pricing system is to overcome the cost plus 
verification process by linking the final price of the product to the same product’s 
price in a list of countries. If the product is an originator then the price will be 10% 
less than the lowest price from the reference list. If the product is a biosimilar the 
price will be 30% less than the price of the locally registered brand. The decree 
caused a hype amongst many of the human rights and patients’ rights groups as it 
was considered a bold step liberating in a way the prices of medicines by linking 
them to international prices18. The Minister mentioned in the last article in the decree 
that an evaluation study to be conducted one year post the implementation of the 
decree to evaluate the impact of such policy on medicines prices however nothing 
was reported by the ministry of health if the study was done and what were the 
results.  
Figure 11 : Summary of the medicine pricing degree 373/2009  
  
                                                            
18
 a court case was filed by the Egyptian Initiative for Personal rights which was lost in its final round and the 
decree was considered constitutional and legal by the administrative judiciary authority 
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Originator (Brand product)
•10% less than the lowest price in 
the reference list of countries
•With the introduction fo the first 
biosimilar the originator's price is 
reduced by 2%  for each year the 
originator was present solely in the 
market.
•The reference list include the 27 
member states of the EU, 
GCC(excluding  Qatar), Argentina, 
Algeria,  
Canada,Japan,Jordan,Iran,Lebanon, 
Sudan, Turkey, India, Philipines, 
Morocco)
•For products manufactured using  
high tech (biotech or other 
sophsiticated technology) a 
comparative pharmacoeconomic 
study to be submitted.
Generic / Biosimilar
•30% less then the originator's price 
if the product was manufactured in 
a facility that passed the inspection 
for Good Manufacturing Practices 
(GMP) from US FDA, European 
Medicines Agency (EMA), Japan,, 
Australia or WHO Prequalificaion or 
any country memebr in the 
International Conference on 
Harmonization (ICH) 
•40% less from manufacturing 
facilities locally approved  by the 
Egyptian Drug Authority only
•60% less from local companies 
which has no manufacturing facility 
but manufactures  in other local 
facilities via contracs (toll 
manufacturing) 
Profit Margin of retail pharmacist/  
others 
•remains the same from the law 
number 314 for the year 1991 
•retail pharmacist's margin 10-12% 
in imported products and 18-20% 
in locally manufactured products
•the consumer price is evaluated 
every 3 years for products priced 
according to this law or in case 
there is a drastic change of the 
currency exchange rate by 15% + or 
- according to the central bank of 
Egypt Currency Exchange Rate.
•Manufacturing facilities are given a  
grace period until 2020 to improve 
their manufacturing and 
operational qualitty standards to 
meet the US FDA, EMA Japan or 
WHO prequalification orICH 
member countries .
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C. The post-revolution pricing decree (499/2012)19:  
The new decree which took place after the 25th of January revolution by Dr 
Fouad Al Nawawi the latest Minister of Health prior to Dr. Ahmed Mostafa 
(Minister of Health) in Hesham Kandil’s government.  The decree didn’t have a 
radical shift in the way medicines are priced, it kept the same external reference 
pricing model. It however changed the distribution of the profit margins for the 
different beneficiaries in the medicine’s supply chain. Any price has three main 
beneficiaries 1) producing company or importing company, 2) distributor or 
wholesaler (may be more than one involved) and 3) the retail pharmacist.   The new 
decree will price the brand product according to the lowest price in the reference list 
of countries. The first 5 generic products the price will be 35% to 40% less than the 
locally priced brand. Each generic after that till the 11th generic (cap) will be 10% 
less than the previous generic.  The new decree mentioned that it cancels the old 
decree 373/2009. Article 6 of the decree detailed the change in profit margin 
distribution between the beneficiaries. It included the creation of two categories of 
products either local or imported.  For the imported the division is between products 
of price less than 500 LE and products of more than 500 LE.  The locally 
manufactured are products either on or off the National Essential Medicines List and 
subsidized products. Figure (13) below outlines the changes in profit margins for the 
different beneficiaries as per the current pricing law number 499/2012. Before going 
in to Table (2) outlining the different terminologies of price components is 
considered crucial. The Ex – Factory price is the price of the product in the factory, 
CIF is called the Cost, Fright and insurance which is how much it cost the company 
to get the product in to the port of the importing country. Then we have the 
distributor or whole sale’s price markup(s) ,the retailer’s markup and finally tariffs, 
taxes and customs20. 
 
                                                            
19
 http://www.eda.mohealth.gov.eg/Download/Docs/499.pdf 
20
 Tariffs, taxes and customs vary from product to product according to importance, global best 
practices is to remove any of these inflation factors to medicine prices to improve accessibility. In 
Egypt tariffs, customs and taxes are applied to all medicines except medicines for chronic diseases 
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Figure 12: Summary of the medicine pricing degree 499/2012 - The post 25th of 
January revolution pricing decree (499/2012) 
 
 
 
Originator (Brand product)
•equal to the lowest  consumer price 
identified  in the list of  reference 
countries in case the brand price is 
identified in more than 5 countries
•In case the price is identified in less 
than 5 countries the above may apply 
or a comparative  study  between the 
originators from different classes for 
the same therapeutic effect
•The reference list (only guiding not 
obligatory ) include the 27 member 
states of the EU, GCC(excluding  
Qatar), Argentina, Algeria,  
Canada,Japan,Jordan,Iran,Lebanon, 
Sudan, Turkey, India, Philipines, 
Morocco) however CAPA has the right 
to review the price in any other 
country in the world and take its price 
in to consideration.
•For products manufactured using  
high tech (biotech or other 
sophsiticated technology) a 
comparative pharmacoeconomic 
study to be submitted and CAPA has 
the right to take a lower price if 
identified before granting the pricing 
decision
Generic / Biosimilar
•Generic:
•35% less then the originator's price 
for the first 5 generics 
•40% less for the  rest of generics (6 
products)
•In case  of  products manufactured 
using high technology such as 
biotechnology (biosimilars):
•30% less than originator price in case 
the product was manufactured in a  
reference country (ICH country) with 
a cap on price not to exceed the price 
of the same product in the country of 
origin or any of the countries it is 
marketed in
•35% less in case it was manufactured 
in a non reference country  with a cap 
on price not to exceed the price of the 
same product in the country of origin 
or any of the countries where it is 
marketed
Profit Margin of retail pharmacist/  
others 
•Profit margins are detailed in 
Figure(13) below
•the consumer price is  reviewed in 
case there is a drastic change of the 
currency exchange rate by 15% + or -
according to the central bank of Egypt 
Currency Exchange Rate OR
•In case the company propose a price 
review for 5% of the total of its 
products per year 
•For the already priced originators, the 
CAPA has the right to review the price 
of the originator post the pricing 
decision in any of the countries in the 
world and incase found  its price less 
than in Egypt it is priced accordingt o 
the new lowest price and  what 
applies to generics prices.
•Margins for retail pharmacist will 
continue to grow by 1% each year for 
already priced products until it 
reaches the new margin
•In case a company stopped its 
manufacturing of a product and 
imported it instead the retail 
pharmacist will continue to have the 
30% margin instead of moving to the 
imported margins category (18-
22.9%) and the difference will be 
borne by the manufacturer
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Figure 13: Profit margin of different beneficiaries in the medicines supple chain 
in Egypt according to new pricing decree 499/201221 
Scenario /price for 
beneficiary 
Local 
Manufacturer  
/ importer 
Profit Margin 
EX factory 
price or (CIF)  
Distributor Profit 
Margin 
From CIF price  
Retail pharmacist profit 
margin in Egypt  from 
distributor’s price 
 For imported products 
with consumer priceless 
than 500 LE: 
 
6.4% 8.8% 
 
22.9% 
 
6.4 from consumer 
price 
 
18% from consumer price 
 
 For Imported products 
with consumer price more 
than 500 LE 
 
6.4% 6.4% 
 
 
18.5% 
 
4.8%from consumer 
price 
 
15% from consumer price 
 
A cap of 150 EGP is 
exercised and in case 
more the difference is 
deducted from 
consumer’s price for 
the benefit of patient 
 
A cap of 450 EGP is exercised a 
difference is deducted from 
consumer’s price for the benefit 
of patient 
 
 locally produced, filled 
or packaged and labeled 
(Bulk) products outside 
the essential medicines 
list 
25% 8.8% 
 
30% + (4.5%of CIF 
price=4.13% of distributor) as 
cash payment incentive = 
34.13%  
25% from consumer’s price = 
29.13% 
products  from the 
National Essential 
Medicines  (local or 
imported) 
 
 
15%  
 
7.86% 
 
25%  
 Subsidized products by 
the government  (local or 
imported) 
NA 4% 10%  
                                                            
21
 http://www.eda.mohealth.gov.eg/Download/Docs/499.pdf 
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IX. The Intellectual Property and Patent Protection in Egypt 
A. Global agreements and Free Trade: The TRIPS agreement 
Intellectual property and access to medicines or commodities of therapeutic 
value have a long history of debate. The debate between access to medicines and 
protection of commercial interests and incentivizing innovation has passed through 
various leaps through modern history. The latest of which is considered a radical 
shift when the agreement on Trade Related Aspects of Intellectual Property Rights 
(TRIPS) was ratified by the majority of world countries to comprise the new world 
order of intellectual property protection. The TRIPS agreement oblige signatories 
(member countries of the WTO) to integrate measures to grant patent protection and 
exclusivity from third party exploitation of a patented invention. Medicines being a 
commodity that affects health is still produced by an entity where return of 
investment is considered a priority on its shareholders’ agenda and will try to exert 
all efforts to protect it from competition to increase profits. One new molecule is a 
result of long years of investment in research and development by pharmaceutical 
companies. The development process of one medicine is outlines in figure (14). The 
percentage of Investigational New Drug (IND) applications that pass through the 
preclinical testing, Phase I, II, III process and is accepted for FDA review process is 
2 from each 10 new molecules. The process itself takes between 12-17 years and the 
time of filing a patent application is usually at the time of filing an IND meaning 9-
13 years from the 20 years patent protection are already consumed before even the 
product is in the market. These entities by corporate law have the right to maximize 
profit and increase shareholders value. Having only one company producing a life-
saving commodity not only introduces monopolistic power but also has profound 
impact on the public health, security and economy. Consequently developing 
countries lobbied the WTO for trade negotiation rounds with a development focus 
that took place in Doha, namely the Doha rounds. Articles to protect public health 
were weaved in to the agreement to ensure protection of intellectual property will not 
affect public health protection.  
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Figure 14: Product development life cycle of innovator medicine according to 
the US FDA22 
 
 
B. Integration of TRIPS in the current Egyptian law number 82 for the year 2002 23 
Egypt was a signatory of the TRIPS agreement in 1995 and joined the World 
Trade Organization in 1996. By singing the agreement countries are obliged to make 
their laws and regulations complying with the TRIPS agreement article or in other 
words “TRIPS compliant”.  Historically the Egyptian law granted patents only for 
pharmaceutical processes but not products so for example if the pharmaceutical 
manufacturer developed a process which increase or enhance a specific product, 
system or another process the patent is given over the process itself but not on the 
final product. This law for the year 1949 granted patents for processes for 10 years 
and for 15 years for products other than medicines. (The trips agreement and Egypt’s 
responsibility to protect the right to health. 2005, January) 
This was replaced in 2002 by law number 82 for the year 2002 (82/2002) , 
however Egypt had a grace period till 2005 till it starts granting patents to medicines. 
The Egyptian Patent office (EGYPO) is the entity responsible for receiving, 
assessing and making decision on patent applications filed in Egypt ( Egypt as other 
                                                          
22
 Power point presentation by Roche Medical department 
23
 http://www.wipo.int/wipolex/en/text.jsp?file_id=126540 
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countries doesn’t recognize patents granted in other territories,  to be granted patent 
for your product protection you have to file a local application). Until April 2009, 
The EGYPO, has 30 legal examiners, 115 technical examiners and 30 
pharmaceutical examiners. The EGYPO received 2800 applications in the mail box 
until January 2005, 80% of which were for pharmaceutical products (UNDP, 2009). 
Patents are granted by the EGPO if the subject application fulfills three criteria: 1-
Inventive step 2- Novelty, 3- Industrial application. Patents in the new law are 
granted for 20 years however the new law although TRIPS compliant has several 
articles which ensures protection of public health and public interest and prevention 
of the abuse in exclusive exploitation of the patent or failing to utilize such 
exploitation by not being able to industrially produce the product in these case the 
government has the right to issue non voluntary license to a third party to produce the 
same patented product.  Such freedom is called TRIPS flexibilities which resulted 
from the Doha declaration24.  
C. TRIPS Plus, data exclusivity and hampering introduction of competition  
A new movement of handling free trade outside the WTO circles are the 
bilateral trade agreements, the most famous of which is the US Free Trade 
Agreements (FTA’s) in such agreements the US and another country agree on 
specific measures to take in terms of economic reform in order to liberate trade in 
goods and services between the two countries with what may result in economic 
prosperity and welfare.  The EU now runs its own free trade agreements which also 
follow suit the US model. The problem with these agreements is the requirements for 
the developing country have to comply with in order to prove economic readiness for 
the developed country. A new type of obligations and strict measures on intellectual 
property protection resulted from such negotiations when the US and EU try to 
protect the interests of their corporates by requesting inclusion of highly restrictive 
intellectual property protection articles in the agreement annexes or what is called 
TRIPS plus. Egypt has gone through FTA negotiations with the US during the time 
of Rashid Mohamed Rashid 25in 2005 but never commenced due to resistance from 
the Egyptian side. The Egyptian Government signed only one FTA with the 
European Free Trade Association countries (EFTA) in 2006. The negotiation rounds 
                                                            
24
 http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm  
25
 Minister of Trade in Ahmed Nazif government 
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included pressures from the Swiss side on Egypt to include an annex that including 
TRIPS plus articles.  The annex would have included articles on granting extensions 
on patents for more than 20 years, patenting enantiomers or same form of the drug 
with different stereotype and for different indication of the same molecule. Egypt 
signed the agreement with EFT countries without signing on the TRIPS plus annex 
on pharmaceuticals with the current head of the Egyptian patent office heading the 
Egyptian delegation’s final rounds of negotiations. One of the major TRIPS plus 
requirements is what is called Data exclusivity (DE).DE in a nutshell is the 
preventing the generic or biosimilar producer from utilizing or referring to the safety 
and efficacy data from the animal and clinical studies conducted by the reference 
product or innovator. 
Development of one new molecule may cost a company around 1 billion 
USD in research, high throughput screening , identification of potential leads and 
then trying these leads in animals , going to Phase I, II and III clinical trials in 
humans. The concept of a chemical generic or a biosimilar that provide a cheaper 
alternative and relies on the innovator’s clinical and non-clinical data in safety and 
efficacy profiles the cost is reduced to 2-3 million USD in Generics and 75-250 
million during a 7-8 years’ time in case of biosimilars (Sandoz, 2013). In case this 
safety and efficacy data can’t be utilized, this will hamper the development of 
cheaper alternatives –after- patent expiry and creates a backdoor for patent extension.  
Currently the US grants 5 years DE while Europe grants 11 years DE. The Egyptian 
patent law currently includes no articles or provisions on data exclusivity however 
article 56-60 details the protection measures for undisclosed information or 
confidential information of commercial value.  
The law provides a maximum of 5 years protection to such information or 
until they are no longer of commercial value whichever comes sooner. It also 
provides a window to the protection of public interest when it mentions in article 56 
of the same law that in case the government find disclosure of such information is in 
favor of protection of public interest this is not considered infringement of the 
patent’s rights. The case of Biosimilars although the head to head clinical 
comparability may reduce the amount of clinical data dependence on originator the 
earlier stages of non-clinical testing to generate safety data requires access to no- 
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clinical and animal studies by the reference product (originator) for safety proof of 
concept.   
D. Data censorship and concerns of Public safety 
Another reason it is important data exclusivity may jeopardize public interest 
is the safety of the product. For the past few years several products has been in the 
market for many years and suddenly withdrawn by their companies at the end of 
their life cycle due to reports on possible life threatening side effects. Examples of 
this are Vioxx™ of Merck &Co and Avandia™ of Glaxo Smith Kline (GSK). 
Regulatory authorities like the US FDA and EMA have fallen under public scrutiny 
because the question then was if these products have been stringently assessed by 
such well-resourced regulatory authorities how come such fatal side effects were not 
reported in the data submitted by the companies at the time of registration.  
Since November 2010, the EMA has released nearly 2 million pages of 
detailed clinical trial information - an approach it says reflects growing public 
demands for more openness to ensure that drug makers cannot conceal adverse drug 
effects. The EMA said it intended to appeal the interim ruling by the European 
Union's general court preventing it from releasing documents until a final decision is 
given. The EMA plans to step up transparency further by establishing a process for 
the release of full clinical trial data, which will come into force on January 1, 
2014."The European Medicines Agency is committed to proactive publication of 
clinical trial data, once the marketing-authorization process has ended. We are not 
here to decide if we publish clinical trial data, but how," said Mario Rasi EMA 
Director General.  (Bryant, 2013). 
 
 
 
  
  
71 
 
Chapter 5: Discussion and Analytical 
findings  
I. Possible Market Failures as a result of the current Government 
regulation of the Biopharmaceutical sector in Egypt: 
In perfect markets the allocation of resources is done in a way that maximizes 
the welfare of citizens, to ensure goods and services that consumers demand are 
produced efficiently and to encourage innovation and broader consumer choice. 
Market failures mean a situation when a market is left to itself and doesn’t allocate 
resources efficiently, and where such situation exists there is potential for 
government to intervene to improve outcomes for business, environment, community 
and the economy (New South Wales Government, 2012). Different types of market 
failures exist including positive and negative externalities, free riding on public 
goods, market powers (monopoly, oligopoly) and information asymmetry. 
Sometimes when governments intervene to regulate a sector, market failures arise as 
a result of such government intervention, leading to what is called government 
regulatory failures. Nevertheless just like medicines every regulation has its side 
effect. Market gains have to be weighed against Market failures to examine the cost 
benefit ratio and when Government intervenes it should be according to regulations 
to avoid using public office for personal gains.  Research findings from the 
interviews with the experts on the three independent variables, (registration process 
of biosimilars, pricing policy and intellectual property regime in Egypt) were 
analyzed. The below section is on the possible failures which may arise from 
government regulation of Biosimilars. Studying possible failures arising from 
government regulations is significant because not only it reduce the markets 
efficiency and public welfare but also it leads to loss of public trust , public scrutiny  
and political unrest. 
 
 
 
  
72 
 
A. Externalities:  
May be positive or negative and in case positive it represents and external benefit 
and in case of negative it represents an external cost. In the case of regulations of 
biopharmaceutical sector in Egypt regulations did not exist until 2009. More than 50 
locally produced biological products (aside from vaccines, plasma derivatives and 
blood products) hit the Egyptian market, some of which are biosimilars some are 
standalone the common thing among them is that they were registered and currently 
in the market without adequate proof of quality, safety and efficacy according to 
international standards or the standards of developed regulatory agencies of the 
International Conference on Harmonization (ICH) to regulate biosimilars. Absence 
of the required regulations (the current guidelines for biosimilars are still in draft 
format) resulted in negative externalities when companies producing biosimilars or 
biologicals of the same therapeutic category using different processes , expression 
system or formulation techniques (standalone) take advantage of the regulations’ 
absence and register their products as generics “chemical generics” following a 
legally legitimate. The regulatory requirements until the 2009 decree didn’t oblige 
manufacturers to provide the required quality, safety and efficacy data relevant for 
registration of a product from a biological origin or do the comparability exercise on 
quality, safety and efficacy. The only requirements was to conduct what is called a 
bioequivalence study (testing the medicines in a small number of volunteers for a 
short period of time) .The main external cost on the society (externality) is the risk of 
public health compromise from these products which we can’t be judged as of lower 
quality, safety or efficacy than their reference products but there is a potential that 
such incomplete regulatory requirements may pose specific risks:  
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 Efficacy risk 
The current biosimilars in the Egyptian market didn’t provide enough data as 
currently required by the draft biosimilars guidelines prepared by CAPA. Data 
needed was head to head comparability exercise with the reference product efficacy. 
Doing a bioequivalence study doesn’t provide such evidence. 
 Safety Risk  
Culture of reporting adverse drug events is still in its early stages (The EPVC only 
started in 2010) with the Egyptian pharmacovigilance center doing a lot of efforts to 
stimulate a reporting culture among health care professionals and users of medicines. 
So even if there is a risk management plan for these companies and a 
pharmacovigilance officer in charge as the demand side the supply side (being the 
consumers and healthcare professionals) has a long way to go. Currently the center 
has around 400 reports on adverse events from the whole of Egypt and no restriction 
was issued on nay biological product as from 2010-201226(EPVC, 2013).  
 
 Economic risk 
Such products are although of lower cost than originators they used for the treatment 
of complex or life threatening diseases such as hormonal deficiencies, liver 
inflammation and cancers. Such diseases require long terms treatment courses , if the 
quality, safety and efficacy of such products are not properly assessed they may lead 
to prolonged illness and  with the current out of pocket payment on health according 
to WHO is standing at around 50% in Egypt27 they may incur catastrophic 
expenditure to cover a single treatment course.   
One case which is worth presenting is the case of the pegylated interferon 
alpha – 2 a used for the treatment of hepatitis C virus induced liver inflammation. 
The case directly touches upon the research dimensions.  It is however worth noting 
that the objective of using this case is not to prove or disprove the government 
decision on registering the Egyptian interferon in 2004 and including it under the 
health insurance reimbursement list. Having the chance through this research to 
interview senior level executives from the producing firms, some clinicians and 
                                                            
26
 http://www.epvc.gov.eg/NewsAttachments/Restrictions%20and%20Withdrawals.pdf 
27
 WHO National Health Accounts estimate the expenditure on medicines in Egypt in 2008 to be 
between 60%  from total health expenditure  
  
74 
 
government regulators provided a chance to analyze the situation and suggest what 
would be a possible way forward for this dilemma. 
The case of the Egyptian Interferon Market Authorization  
i. Hepatitis C virus in Egypt: Public Policy relevance of the problem:   
Globally, approximately 150 million people are infected with hepatitis C 
(HCV) and it is estimated that 350,000 people die each year from HCV-related liver 
disease(WHO,2012). Egypt has among the highest rates of HCV in the world at 22% 
(Wiktor, S., 2013),meaning almost one in every 4.5 people may be infected with 
hepatitis C virus in Egypt’s population of around 90 million people . In some studies 
it was mentioned that 500,000 new cases of hepatitis C virus are reported every year 
(WHO GAR, 2009). These figures are alarming and should be taken seriously by the 
post-revolutionary government of Egypt. The public policy relevance of the problem 
is hence, unquestionable, government and politicians should design and implement 
policies to combat such diseases that are evidence based and which would achieve 
the target objectives set to develop the country.  
ii. Socioeconomic impact of the problem: 
The effects of such disease burden are immense in terms of the economic 
power wasted via lost working days, workforce, hospitalizations and unnecessary 
expansion of healthcare budget. The treatment costs are increasingly posing a 
problem in countries like Egypt where until this moment there is no clear public 
health insurance policy communicated by the government. The health insurance 
system set up by the government in mid-nineties proved unsuccessful in terms of 
equity (leaving out agriculture workers and other workers in the informal sector) and 
quality of service rendering many beneficiaries unsatisfied. The government in 2009-
2010 began to develop a draft law for health insurance that would achieve the 
principles of universal health coverage based on equity and health as a human right 
principle. Therapy for hepatitis C is extremely expensive, making it largely 
unaffordable. The availability of full or part government funding for treatment of 
hepatitis C depends heavily on the income status of a country: such funding is 
available in 83% of high income, 77% of middle income, and 33% of low income 
countries respectively (MSF Access Campaign, 2013).  The above situation has very 
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much affected ability to access medicines in the country. In the case of hepatitis C 
treatment the treatment options were all imported as it remained under the patent so 
no cheaper versions were available. 
iii. Hepatitis C Virus Induced Liver Inflammation treatment: 
The treatment of hepatitis C virus have developed along the course of years 
since its discovery in 1989 into complex protein based molecules that are able to 
stimulate the immune system to attack the virus while at the same time be more 
selective and thus reduce the treatment course side effects. The current treatment of 
choice for the virus is called (Pegylated interferon alpha 2 –a or b). The product has 
been produced globally by two companies Roche from Switzerland and Schering 
Plough from the USA (now part of Merck pharmaceuticals global). Until 2004 there 
were no medicines within the biosimilar/standalone for hepatitis C treatment in the 
Egyptian Market until a joint venture between a German biotechnology company 
namely “Rhein biogenetics” and an Egyptian company “Mina Pharm” managed to 
produce the pegylated interferon for the treatment of hepatitis C and registered it in 
the Egyptian Ministry of Health. The product named (reiferon retard) was priced at a 
third of the two other competitors,  The rationale for treatment of chronic hepatitis  is 
to reduce inflammation, prevent progression to fibrosis, cirrhosis, and finally 
hepatocellular carcinoma (cancer of liver cells) through the eradication of the virus in 
chronically infected patients.  
iv.  Addition of polyethylene glycol (PEG) moiety to protein may result in: 
 Prolonged plasma half-life 
 Reduced clearance 
 Less immunogenicity 
v. Characteristics of pegylated proteins depend on: 
 Structure of PEG moiety (e.g., size, branching, linkage bond strength) 
 Site(s) of attachment to parent compound 
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Figure 15: comparison between effects of different IFN type’s overtime28 
vi. The EASL Clinical Practice Guideline on Management of hepatitis C virus infection: 
 The combination of pegylated IFN-aand ribavirin is the approved Standard of 
Care (SoC) for chronic hepatitis C. 
 Two pegylated IFN-a molecules, pegylated IFN-a2a (180 lg once per week) and 
pegylated IFN-a2b (1.5 lg/ kg once per week), can be used in combination with 
ribavirin29. 
 No other types or Pegylated Interferon are mentioned in the international 
practice guidelines 
vii. The debate on interferon’s for treatment of hepatitis C patients in Egypt:  
There is a heated debate that started in 2011 on the Egyptian interferon in 
Egypt with two points of view one advocating to withdraw the product until further 
assessment based on the right regulations to ensure safety, efficacy and quality and 
the other is pro the product as it provides a safe haven for the government to provide 
low cost treatment for a growing number of hepatitis C patients and it proved 
effective in maintaining a Sustained Virological Response (SVR). 
The Egyptian interferon is also a new window for local production of 
biological products using technology transfer. The Egyptian government was and is 
still facing a challenge to provide affordable treatment to HCV patients using the 
                                                          
28
 PowerPoint presentation by Roche Egypt Medical department 
29http://www.who.int/selection_medicines/committees/expert/19/applications/Pegyinterferon_6_4_3_A
_Ad.pdf 
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treatments for HCV, due to budget constraints. The current annual MOH 
procurement value for pegylated interferon is almost 3 million Egyptian pounds from 
the Egyptian interferon excluding the health insurance procurement tender value 
which represents as quoted from an ex CAPA director “a total of 700 million EGP” for 
hepatitis C treatment in Egypt. The value for treatment of hepatitis C allocated by the 
government through MOH, liver institutes and the Health Insurance Organization 
tenders is 25% of the total annual budget available for procurement of all types of 
medicines by the MOH (2011-2012 tender value stood at 2.8 billion Egyptian 
pounds)30. 
The decision to register Reiferon retard relieved such high burden from a 
price of more than 1000 EGP for one prefilled injection to be used for a 48 treatment 
course to 217 EGP for the Reiferon retard representing 1/5th of the originator’s price 
at that time. However the price of 1000 EGP was in private sector (retail pharmacies) 
and a series of negotiations between the producing company (Roche) and the 
government resulted in a lower price of 250 Egyptian pounds for the Swiss interferon 
imported as bulk , only labeled and undergoes secondary packaging in an Egyptian 
manufacturer named Memphis pharma (new trade name Pegferon). The agreement 
with the government encouraged the inclusion of the Roche’s product in the MOH 
tender however the health insurance organization didn’t approve Pegferon’s 
inclusion in its reimbursement list. As per Roche: a request was done to establish a 
record for patients receiving/reimbursed for pegylated interferon from the health 
insurance to monitor their SVR and clinical success rate but it was rejected by the 
health insurance organization and no reason was given for this refusal. 
 
 
 
 
 
                                                            
30
 Total Pharmaceutical Expenditure in 2008 stood at 8.3 billion EGP as per the last round of National Health 
Accounts in Egypt 
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viii. The Argument of Roche Producer of the originator PEG-IFN ( Pegasys™):  
As a research based company that invests in high risk research to produce 
innovative medicines, the company was not in favor of a competitive product to take 
part of its market share. The WHO 19th expert committee for selection and use of 
essential medicines received a request in 2013 for inclusion of the pegylated 
interferon alpha-2-a and b on its essential medicines list31. The application included 
that there are currently few biosimilars however none are registered in a stringent 
regulatory authority of ICH country and due the absence of a WHO prequalification 
system for such products it is very hard to ensure there quality, safety and efficacy at 
an international standard (Witkor, 2013).  The Roche product Pegasys when 
launched in Egypt was the market leader, the government had no choice of procuring 
it with an inelastic price demand. It was the only pegylated interferon on the health 
insurance list. The Egyptian interferon when introduced in 2004 raised the concerns 
of Roche and hence Roche started to negotiate with the government reduction in the 
price of its imported product that went down from 1000+ EGP 600+ EGP 400+ 
EGP until an agreement was reached on the second brand for Roche (local secondary 
packaging) and reducing the price to 250 EGP to be competitive with the Egyptian 
interferon.  
 
Figure 16: Egyptian Government’s demand for originator pegylated interferon 
(Pegasys™ from Roche) prior to registration of the Egyptian interferon 
(Reiferon Retard™ from Rhein Mina Pharm) 
The company in parallel started to question the therapeutic value, safety and 
efficacy profiles of the Reiferon retard.  The below table 10 compares both products. 
                                                          
31
 The WHO Essential Medicines List (EML) stands as a guide for countries to select the most essential 
medicines in their national procurement decisions 
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Table 10: Summary of indicators comparing Pegasys and Reiferon Retard 
(Egyptian Pegylated Interferon) 
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ix. The argument of Rhein-Mina Pharm producer of the Egyptian Interferon 
(Reiferon Retard™): 
The Joint Egyptian – German venture that represents a leap in 
biopharmaceutical production in Egypt have a direct and straight forward argument 
on the allegations of its competitor. That is the product although was registered as a 
chemical generic it has been in the market for more than 8 years now and is proven 
to be effective. Evidence on this has been published in 2 clinical studies done by 
Egyptian clinicians on Egyptian patients of geno type -4 (special viral geno type 
where majority of Egyptian patients are infected with)32.  The company considers the 
product a Stand Alone follower rather than a biosimilar due to the origin of the 
bacteria (expression system were the recombinant gene is ingested and protein is 
produced) is different than the originator33 also because of the pegylation process and 
attachment technique are different. The product also still represents a more economic 
option than the Roche product. 
x. Proposed way out of the dilemma: 
At the time of renewal of the market authorization license (registration). Two 
scenarios may exist to apply the biological assessment on the Reiferon retard to 
ensure its quality, safety and efficacy. The decision will depend on how the Egyptian 
regulatory authority will define Reiferon retard. The author is of the opinion that 
Reiferon Retard should be treated as a Stand-alone follower and not a biosimilar due 
to reasons mentioned above. 
 
 
                                                            
32
 Number of subjects in the clinical studies for Pegasys done on Egyptian patients of geno-type 4 
hepatitis C virus were 140 subjects in two studies done by Thakeb et al and ANRS 1211 while two 
other studies by shobokshi etal and Diago etal with 60 and 49 subjects were conducted in Saudi Arabia 
and Germany respectively on geno type 4. 100 subjects for Reiferon retard first study done by Esmat 
etal : “Evaluation of a novel Pegylated-Interferon alpha 2 a (Reiferon-Retard®) in Egyptian Patients 
with Chronic Hepatitis C – Genotype 4”  and 107 for the second study done by Taha etal , named “ 
efficacy and safety of the novel Pegylated-Interferon alpha 2 a (Reiferon-Retard®) in Egyptian Patients 
with Chronic Hepatitis C – Genotype 4”  
 
33
 Originator uses E.coli and Reiferon Retard use Hansensula strain 
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 Reiferon Retard as a Stand Alone:   
The product will have to provide a full dossier based on the guidelines set in 
decree 297 for the year 2009, including full quality CMC, safety and efficacy data. 
As Reiferon Retard in this case will not rely on the reference product safety and 
efficacy data, hence the abridged pathway of biosimilars will not apply. This 
situation may represent a huge investment by the manufacturer in nonclinical and 
clinical studies. The product is currently the only pegylated inteferon on the health 
insurance list and hence will cause disruption in healthcare budget if withdrawn or 
suspended until the new safety and efficacy studies are finished, data assessed and a 
decision is made. The disruption may be caused by the fact that when Roche is the 
sole supplier a price review may be requested which may lead to an increase in the 
product’s price that may overburden an already exhausted medicines procurement 
budget.  Shortages may occur and patients treated with interferon may develop a 
“breakthrough”34 due to disruption in the treatment course (unavailability at some 
weeks as many patients attend to the public healthcare center weekly to get the 
injectable shot). To avoid such scenario the government may: A- keep Reiferon 
retard in the market and reimbursement list while conducting the requested  studies 
by the government 2-In case the government decides to withdraw or suspend the 
market authorization until the data is supplied , the government may consider signing 
an agreement with Roche for supply with legally binding  terms which won’t allow 
for a price review for the period Roche’s product is solely in the health insurance 
reimbursement list, MOH and liver institutes lists while the reiferon retard is 
undergoing its safety and efficacy trials. In case the Reiferon retard failed to show 
acceptable safety and efficacy data, the agreement may be reviewed to allow for 
price change based on the pre-set pricing policy of the government. 
 
 
 
                                                            
34
 A term given when an increase in the virus in the blood occurs during the treatment course, possibly due to interruption of the 
treatment course 
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 Reiferon retard as a Biosimilar:  
1. In this situation the product will rely on Roche’s Pegasys™ safety and efficacy 
data but will have to develop a complete comparability exercise on quality 
attributes including complete characterization of Reiferon Retard 
physiochemical, purity, structural and biological action versus Pegasys’s data. 
In case the quality exercise shows acceptable similarity the safety and efficacy 
data levels will then be conducted. 
In both cases depending on how developed the pharmacovigilance system of the 
company, the individual and periodic safety reports available (ICSR and PSUR’s) on 
Reiferon Retard and the possible risks identified by the reference product (Pegasys) 
Risk Management Plan (RMP) are to be assessed. This includes Phase IV (post 
marketing) studies. In addition warning boxes on any possible safety issues may be 
added to the package and package insert to further minimize the risks. 
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B. Information Asymmetry and potential hampering of competition: The “Box” 
system in the market authorization process:   
The first step in the registration process of any medicines in Egypt is an 
application for checking if there is an empty slot in the 12 available slots of the 
“Similars Box”. The box system as it stands is the tap which control how many 
similar versions of the same medicines the government is authorizing for marketing 
in the national market.  
Currently it allows the first originator product and then 11 generics one 
imported and the 10 has to be locally manufactured to encourage local manufacturing 
in Egypt. In case of products produced using advanced technology like rDNA and 
other Biotechnology techniques, the current situation is 1 originator and 5 imported 
and 6 locally manufactured. Reasons being , these products are produced by 10-14  
local manufacturers  which are still developing  limited capacity in terms of 
technology development or transfer. Since the market needs are much higher than 
local supply a wider importation window was  set at 5 biosimilars  or biogenerics.  
The box system was heavily criticized from many of my interviewees as its only 
merit  is that it reduces the work burden on CAPA because it limits the number of 
application from a specific class of products and hence the number of required 
quality, safety and efficacy assessments needed to be done by the government 
agency. 
 
Figure 17: Box System for Generic medicines Market Authorization Application 
in Egypt 
Orginator/brand 
product
•Only one product by 
definition can be 
registered
Generics imported 
•1  product can be 
registered
Generics 
manufactured locally 
•10 products can be 
registered
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Figure 18: Box System for Biosimialrs Market Authorization Application in 
Egypt 
The main regulatory failure that might arise from this system is lack of transparency 
and inefficiency in this system that may lead to anticompetitive behavior, imperfect 
competition and increase the potential for lower quality products. To elaborate more 
the below examples are given: 
i. Scenario 1: Company A has sent an application to CAPA for inquiry on 
availability of a slot in the “similar box” the box had 2 slots empty and 
Company A was informed by CAPA on the availability of a slot for registration 
of company A’s  biosimilar.  Company A owner also owner of another company 
named Company B which produces the same biosimilar under another trade 
name and in another facility. The owner of Company A knows someone in 
CAPA who has access to the “similar box” and can pass through the 
information about the availability of a final slot for this product. Meanwhile 
Company C which is a local manufacturer wants to invest in this area and now 
wanting to apply for registration of the product a 3rd biosimilar of the same 
product.  The owner of Company A and B knew about the plans of Company C 
and want to deter such potential competition so he applies for the final slot 
under Company B due to his access to the censored Box data. Now the box of 
similar is full and blocked the registration of Company C. Company C applied 
only one day after Company B occupied the last empty slot in the box and 
inquired about the availability and received a negative reply that the box is full 
and he has to park his application on a waiting list until a slot is empty.  This 
hypothetical scenario may or may not happen in reality. The importance of a 
system which is available in the public domain may reduce the vulnerability of 
Orginator/brand 
product
•Only one product by 
definition can be 
registered
Biosimilar imported or 
final bulk
•5 products can be 
registered
Biosmilar 
manufactured locally 
•6 products can be 
registered
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such anticompetitive practices. An online system displaying the situation of 
slots for each product without mentioning the names of the applying companies 
to keep commercial confidentiality is an option CAPA may want to take in to 
consideration.  
ii. Scenario 2: Under the newly proposed draft guidelines for biosimilars in Egypt 
-  explained in the data analysis section-  a company after occupying a place in 
one of the eleven slots available in the box (5 imported-6 locally manufactured)  
has 3 years to complete its studies and then the studies are assessed for an 
acceptance/rejection decision. This implies that for the companies that the faster 
you apply the less risk you face because you won’t lose anything by occupying 
a slot in the box system and blocking others and in case study results reveals 
positive the company may continue in its application and if failed its occupation 
to the slot in the box did not cost it anything aside from the registration fees35. 
The inefficiency arises from the fact that this area of biosimilars is an area 
where Egypt needs to start promoting local investment and manufacturing to 
strengthen access to these affordable medicines.  Now  back to example 1 in 
case the last two slots available are being competeted against with three 
companies A,B and C. Company A and B applied before company C which 
has a much more success prospects and stronger profile in terms of quality ( 
already exporting to US and Europe from the same facility) and investment 
capital than company A or B. Company A and B spent 2 years generating 
their quality and safety data and only company A’s biosimilar showed positive 
similarity profile of quality, safety and efficacy while company B’s biosimilar 
had serious safety issues with few patients developing immunogenetic reactions 
during immunogenicity study. Company B’s product was rejected and now a 
slot is open company C  can now apply but after 2 years lag time were the 
investor (company C owner) changed his mind about investing in biosimilars as 
the current regulations is not encouraging investors by limiting the number of 
applicants to marketing authorization. 
 
 
                                                            
35
 Currently set at 100 EGP for local manufacturer 
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iii. Information asymmetry and its effect on product quality: The issue of lack 
of transparency and asymmetric information has a significant effect on 
product’s quality. There is always a probability that some very good players 
who can produce quality products are present yet not knowing this information 
and hence the consumer is affected because the information is distributed in a 
manner were not all potential players are informed and hence the probability of 
missing the best quality products remains a significant result of information 
asymmetry.  
iv. Possible solution:   
CAPA may consider removing the Box system for 
Biosimilars/biopharmaceuticals due to the following reasons: 
1. It limits competition which increases supply and may reduce prices leading to 
improved access  
2. It is not encouraging local investors in an area Egypt has to focus its efforts to 
promote local investment and attract foreign direct investment  
v. The box system may be a funding source to build inspector’s capacity 
The main argument of the government is that “if we open the box with no cap or 
limit we will get until may be 55 generics or similar of the same medicine” (quoting one of 
my interviewees from CAPA). Each generic follows a 10 % decrease in price than 
the previous one. The argument is that the 13th or 14th generic with the presumably 
very low market price given to the company in order to compromise that low price 
versus costs, the company will be manufacturing using raw material and active 
ingredients imported from a manufacturer of unacceptable quality standards. The 
argument is easily refuted that CAPA may conduct Good Manufacturing Practices 
(GMP) Inspection Audits to the Active Ingredient (Drug Substance) manufacturer 
usually in India and China (representing 80% of global supply) to assess their level 
of GMP compliance.  
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vi. To make use of the potential missing opportunity 
The other argument is that the current inspector’s capacity can’t inspect 
Active substance producer and can only inspect finished product producer (FPP). If 
the box system is to continue, the government may consider opening extra slots with 
a higher registration fee that is pooled in a fund for regulatory capacity building to 
train CAPA inspectors on auditing Active Ingredient Manufacturers and hence 
developing an asset that may remain in house for years and can later transfer the 
knowledge to others, while increasing competition, reducing price, improving access 
without compromising on quality. Meanwhile regulatory collaboration paying a 
nominal fee outsourcing or semi-sourcing out the assessment of the active 
ingredient’s master file or its GMP inspection with a more developed regulatory 
authority like in Saudi Arabia or Jordan or making use of other bilateral or 
multilateral agencies like WHO, US FDA or EMA can ensure the quality of the 
products and serve to transfer knowledge between the Egyptian authority and more 
developed regulatory systems. 
C. Collective action groups (The pharmacist’s syndicate versus the Industry 
chamber): politicization of regulations: the new medicines pricing decree 
(499/2012) 
The latest pricing decree which was out in June 2012 created a wide hype 
among stakeholders in the healthcare sector. Price being a major driver for patient’s 
access should be fair to all parties involved producer, user and payer. The pricing law 
as explained in the data analysis section changed the profit margins for pharmacists 
to be one of the highest in the region. A comparative table below shows the profit 
margins prior to the 499 decree, post the decree in Egypt compared to margins in 
wealthy countries such as Saudi Arabia and UAE. 
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Table 11: Comparison between average profit margins for retail pharmacist 
across Egypt, UAE and Saudi Arabia36 
Margin for 
beneficiary per 
country 
Retail pharmacist 
profit margin in 
(314/1991) and 
(373/2009) 
decrees 
Retail 
pharmacist 
profit margin in 
Egypt  
(499/2012) 
decree 
Retail 
pharmacist 
profit margin in 
UAE  (decree 
834/2008)37 
Retail 
pharmacist 
profit margin in 
KSA  (Saudi 
Pricing Policy) 
For imported 
products  
 
10-12% 20.7%  19.75 % 
 
 
15%38 
locally produced, 
filled or packaged 
and labeled (Bulk) 
products  
 
18-20% 21.6%  
 
21%  
 
 
15% 
 
 Advantages of the new pricing decree 499/2012 
Aside from being favored by all retail pharmacists and owners of retail pharmacies, 
the new decree has a public health advantage by setting a cap of 450 EGP in profit margin 
for the retail pharmacist which is exercised by deducting the difference from consumer’s 
price for the benefit of patient.   So in case a product is proposed for the pricing committee 
as 3500 EGP consumer price setting the retail pharmacist’s margin at 525 EGP. The 
consumer price is deducted till it reaches the 450 EGP maximum which is translates to 3000 
EGP patient’s price making a 500 EGP deduction from consumer’s price. However this is 
only applicable for imported medicines more than 500 EGP. 
 
 
 
                                                            
36
 Margins were listed in different countries legal documents as % of different prices (distributer’s price 
or CIF/ex-factory price) and expressed for different categories (imported/local, chronic 
medicines/antibiotics, etc...). For comparison purpose: The proposed table rounded all figures to one 
denominator (retail pharmacist margin as % of distributor’s price) 
37
 http://www.tamimi.com/en/publication/publications/section-3/june/prices-discounts-on-drugs.html 
38
 The tier System in Saudi Arabia Pharmacy Profit for local products (SR50 or less 20% , Greater than 
SR50 – SR200 15% , More than SR200 10% ): http://212.100.220.58/NR/rdonlyres/DE3C597F-9499-
47D5-9A32-1D6E82AF0152/0/SaudiPricingGuidelinesandTheProposedNewSystem.pdf 
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 Disadvantages of the new pricing decree:  
 
1. Increasing barriers for investment in local production of biosimilars: 
 The new decree was faced by a huge hype from the manufacturer’s side 
especially local manufacturers because the increase in the retail pharmacist profit 
margin was cut from the manufacturer’s margin. The syndicate of pharmacists was 
the main lobbying body behind this decree. The syndicate lobbied the minister of 
health Dr. Fouad Al Nawawi and provided reports showing that manufacturing 
companies in Egypt achieve profits between 20-30% according to the manufacturer’s 
reports in the stock markets. The retail pharmacists are facing increasing prices of all 
other basic commodities in Egypt and their salaries are low due to the very low profit 
margins given under the previous law. Manufacturers on the other hand disagree with 
this and interviewing a senior executive of the industry chamber he mentioned that 
with the current spike in USD dollars exchange rate many - quoting him “Devaluation 
reached 30% and they are getting the USD for 8.30 EGP from the black market” - 
manufacturers now are facing a problem that they are not able to achieve “break-
even” for many of their products leading them to either stop its production as they 
are losing or not abiding by the new decree by continuing with the old system . This 
lead the MOH to send inspectors for the first time to check manufacturers 
compliance and auditing price receipts selling to distributers and retail pharmacies. 
The production of biosimilars is a complex process compared to production of 
generics in terms of the time needed (2-5 years), risk imposed (variable behavior 
among batches may lead to rejection of batches and loss of money), monetary 
investment (number of studies needed and comparability exercise with reference 
product). Such decree will not encourage local producers to continue investing in 
these life-saving drugs and critical industry, they will rather shift to less risky and 
easier business to generate quick profits. The decree has to create balance and deal 
with the biopharmaceutical industry outside the scope of such decree to provide and 
advantage of producers in this area. 
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2. The decree doesn’t provide pricing incentive for improving quality: 
In the pre revolution decree of Hatem El Gabaly the decree provided 10% 
preferential pricing incentive for generics produced in manufacturing facilities which 
passed the quality inspections (GMP, etc..) of the US FDA, European Medicines 
Agency (EMA), Japan or WHO or any other country member in the ICH consortium. 
The new decree didn’t mention anything on this article and cancelled the old decree 
hence cancelled this 10% preferential pricing for manufacturers who provide 
evidence for quality operations meeting international standards. The decree however 
mentioned the biosimilars (referred to in the decree as hi tech generics) imported 
from ICH countries will get a 35% reduction while those imported from non-
reference will get 40% reduction in price than originator. The decree didn’t mention 
about locally manufactured , in case assuming the high tech locally manufactured are 
equivalent to the non-reference countries imported the price incentive will still be 
less than the 373 decree standing at 65% of the originator’s price while the 373 
decree provided a 70% of the originator’s price, difference of 5%.  
3. Distribution of pharmacist profit margin is not encouraging local production of 
essential medicines:  
Essential medicine list includes the medicines which are based on national 
public health needs representing the public health needs for the majority of the 
population. These medicines are crucial to be present in all public health facilities at 
least. The profit from locally produced was deducted by 7-12% from manufacturer to 
retail pharmacist. For essential medicines products which are crucial for the majority 
of the population the profit margin of the manufacturer was reduced between 5-15% 
to the retail pharmacist. 
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Table 12: Decree 499/2012 retail pharmacy and manufacturer’s profit margin 
distribution for locally manufactured products 
Production type Manufacturer’s 
margin 
Retail pharmacist’s margin  
locally produced, 
filled or packaged and 
labeled (Bulk) 
products outside the 
essential medicines 
list 
25% 30% (encouraging for pharmacist but not good 
for manufacturers ) 
 
 
Products from the 
National Essential 
Medicines local or 
imported) 
 
15% (not 
encouraging) 
 
25% (encouraging for dispensing and 
discouraging for production) increase over the 
previous by 7% so may negatively affect 
production of Essential medicines 
 
4. Shortages in medicines as a result of the 499/2012 pricing decree:  
The government is currently facing implications of the latest pricing decree as 
more than 500 types of medicines are in shortage due to various reasons. CAPA 
setup a medicines shortage unit in order to respond to such crisis, with the objective 
of investigating and reporting medicines shortages and its reasons and facilitating 
possible solutions. Quoting one of my interviewees working for the drug shortage 
unit in CAPA “around 25% of drug shortages can be attributed to the new pricing decree. 
We conduct interviews with manufacturers who stopped producing the medicines in short 
and many of which relate such stoppage to the impossibility of reaching breakeven with the 
new pricing decree”. From the biopharmaceutical/biosimilars which faced shortage as 
a result of the current pricing decree is Human chorionic gonadotropin hormone 
produced by EIPICO which is the sole producer. The other categories included 
almost all categories of medicines with varying shortage levels. Figure (19) shows 
the reasons for shortage as reported by the medicines shortage unit in CAPA. 
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Figure 19: Reasons for medicines shortage as reported by the Drug Shortage 
Unit in CAPA 
 
25%
20%
15%
10%
5%
10%
10%
5%
Reason for Shortages
Statistics from the monthly drug shortages report 
by CAPA (Feb 2012)
Low price (new pricing decree)
export oriented manufacturer(priority to export markets)
sole manufacturer’s drug product
closed production line
Financial  problems
Unexpected Increases in Demand and late  NODCAR report
late re-registration or variation problems
import approvals delay
  
93 
 
 
Figure 20 Medicines Shortages during the month of March 2013 in Egypt - 
Drug Shortage Unit -CAPA 
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Several meetings took place between the two lobbying bodies and the 
regulatory body (CAPA/MOH) to reach a consensus. The presidential authority 
realizing the size and magnitude of the problem ordered the central bank to instruct 
local public and private banks to provide hard currency (USD) to pharmaceutical 
industry needs and to facilitate the importation process of raw materials.   
The government also is trying to respond to the shortages of life saving 
medicines by opening the box for registration of these medicines and providing 
facilitated importation and fast track registration procedure for such medicines.  
This may solve the problem in short term however on long run, the local 
production may be negatively affected. Putting in to consideration that local 
production in Egypt depends on 130 manufacturers which supply the market with 
82% of its needs , quoting a senior executive in the Egyptian pharmaceutical industry 
chamber ”56%  of needs are produced by multinationals -18% of which are imported and 
38% locally produced, 4% from holding companies or government companies the rest 40% 
come from private local manufacturer” is facing significant losses while the 
government become more and more dependent on imported products. From these 
130 only 10 are producing biotechnology based biopharmaceuticals between 30-40 
products (including heparins, epoetins, insulins, hormones,GSF’S, interferons, etc..) 
are currently registered or under registration from a total of 344 registered 
biopharmaceuticals representing  between 10%-12% of market needs.  
The pricing decree until these lines is under discussion by various 
stakeholders within CAPA including the pricing committee with the possibility of 
reviewing it to stop the current problems to increase the number of local 
manufacturers focused on this area. 
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Table 13: Table 13: Local producers of biosimilars in Egypt and their area of 
production focus 
Manufacturer’s name Area of biopharmaceutical/ biosimilar 
production (including bulk filling , 
labeling and packaging final bulk) focus 
1. (EGYVAC) and affiliated company of the Holding 
Company for Biological Products and Vaccines 
(VACSERA) 
Vaccines, Insulin, antitoxins, antivenoms, 
urokinase 
2. Egyptian International Pharmaceutical Industries Co. 
(EIPICO) 
Human Growth Hormones, menopausal 
chorionic gonadotropin 
(FSH+LH),erythropoeitin 
3. Rhein Minapharm Co. r DNA technology producing: Pegylated 
Interferons, anti inflammatory proteins, 
Human Pituitary hormones 
4. Sedico Insulins, streptokinase, urokinase,filgrastim 
5. Eli Lilly/Egypt Insulins 
6. ACAPI Interferon alfa 
7. El-Nile Co. Erythropoietin, interferon alpha-2a,2-
b,granulocyte colony stimulating factor(G-
CSF), Human Chorionic Gonadotropin 
8. CID Heparin 
9. Amoun Erythropeitin,heparin, 
10. Otsuka Interferon Alfa 
11. ACDIMA Interferon Alpha-2a, Streptokinase 
12. Amriya Fellotropin, HCGonadotropin,Human 
menopausal Gonadotropin (HMG) 
13. Marcyrl Urofollitropin (FSH) 
14. Alexandria Heparin 
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Reflections on the rent seeking behavior and public choice theory in relation to 
the latest pricing decree 499/2012:  
Nobel Prize winning economist Michel Buchnan sat the foundation of the Public 
choice theory and its players. The idea in a nutshell is that elected government politicians, 
government officials are taking their decisions which may affect the public based on several 
other factors than the public’s interests amongst is the pressure from lobby groups and 
special interest groups who may be rent seeking trying to shape the regulatory framework to 
benefit their own interests. In other words, public choice is an application of neoclassical 
economic tools (self-interest and utility maximization) to explain political behavior 
(P.O.Lee, n.d).   
A. The stakeholders of the public choice theory: has been exemplary fitting in 
the pricing decree 499/2012: 1) Government represented by the Minister of health 2) 
special interest group represented by the syndicate of pharmacists and The 
pharmaceutical industry chamber which is another special interest group seeking rent 
3)the patients access to medicines is the public interest. 
B. Analysis of the dynamics between the latest medicine pricing decree 
stakeholders: The new pricing decree came up after almost one and half year of the 
revolution, the economic situation was getting worse due to the post revolution 
economic recovery phase, military rule and lack of interest from foreign direct 
investors in Egypt. The freedom and justice party won majority of the parliament 
which was later dissolved and majority of the seats on executive boards of most 
professional syndicates. The Syndicate of pharmacists was no difference with a 
board composed of almost 85% from the FJP39. The programme of the syndicate 
promised the long sought after request of increasing profit margins for pharmacists to 
improve their economic standards being one of the highest educated/respected strata 
in the Egyptian society. Many youth groups within the syndicate waived to the 
syndicates that in case promises made weren’t fulfilled the current board will be 
thrown away in the buildup of the post-revolutionary Categorical demands hype 
made by several professional sects including (doctors, teachers, transportation 
authority workers, etc…). The situation in Egypt was absolutely far away from 
bearing any policy that would increase medicine prices on consumers (i.e.: patients). 
The presidency elections were ongoing and a FJP candidate has a 50% chances for 
                                                            
39
 Voting majority  
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winning so the other player represented by the Minister of health was also seeking 
self-interests in remaining in the post elections government (reason for such 
assumption is that the decree was signed after the presidency elections were 
announced by the winning of the FJP candidate-current president of Egypt – Dr. 
Mohamed Morsi). The decree unfortunately was not well received by the 
manufacturing sector and the industry lobby reacted aggressively by not abiding by 
the decree and by stopping the production for some essential medicines also seeking 
their self-interests trying to pressure the new government  to change the law to the 
old margins or increase prices. Unfortunately the public interest was not taken into 
consideration where patients are now suffering shortage in accessing some medicines 
and in the near future the industrial capacity of Egypt in this strategic sector may be 
jeopardized due to many manufacturers stopping production, selling their facilities or 
production lines and facing financial difficulties. 
 
Figure 21: Dynamics of Public choice theory in Egypt's medicines pricing decree 
Photo credits: policyinnovations.org 
Syndicate of 
Pharmacists
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lobbying for increased 
retail pharmacists 
profit margins
Govenrment 
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consequences to 
Pharmaceutical 
Industry 
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• rent seeking by exerting 
pressure on government 
through inducing drug 
shortages
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Chapter 6: Conclusion and Policy 
Options:  
This study aimed at examining the current regulatory policy in Egypt 
pertaining to regulation of the biopharmaceutical sector and with emphasize on the 
regulations of biosimilars as a key component of this sector. The government 
regulatory interventions are usually in place to dispel market inefficiencies, failures 
and restores balance. Despite being a highly regulated sector little attention is given 
to studying the government interventions and possible failures of such interventions 
in the medicines sector in general and the biopharmaceutical sector in particular.  
The government of Egypt is faced with a challenge to regulate biosimilars 
after many of which have been approved in the country as generics and thus not 
following international standards in assessment of the QSE of such critical lifesaving 
products.  Legislative and regulatory gaps exist on how to deal with this negative 
externality of similar copies of biologicals which has been registered prior to the 
2009 decree as chemical medicines and being marketed freely.  The process of 
registration itself proved to have potential for improvement in terms of curbing 
process’s vulnerability for anticompetitive behavior, improving transparency and 
increasing efficiency of operations.   
The intellectual property protection regime in Egypt is welcoming to local 
producers. The law number 82/2002 complies with the TRIPS agreement and 
provide patent protection for medicines for 20 years from the date of filing yet it 
possess many articles which represents flexibilities for the government to revoke, 
invoke or issue licenses voluntarily and compulsory to local producers if public 
health is at danger. The Minister of health has special power to cancel granted 
patents by the EPO for 60 days post granting the patent for public interest’s 
protection reasons providing less risk for local producers to venture in to producing 
biosimilars backed by a supportive IP protection legal framework.  
The area of local production is potentially hampered by the latest pricing 
decree 499/2012.The decree redistributed profit margins between retail pharmacists 
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and producers leading to unintended consequences of drug shortages, financial 
implications on producers and potential closure of production lines of some 
manufacturers. The study finally examined the dynamics of the latest pricing decree 
in the context of one of the theories of modern political economics namely the public 
choice theory. The potential for rent seeking behavior by different self-interest group 
and government on the expense of public interest is something that leads to 
regulatory inefficiencies in fixing market failures.  
The area of production of medicines using advanced biotechnological 
technique is currently at its primary stages in Egypt with a very small number of 
local producers of few items, mainly overlapping. This area has potential for growth 
if the government adopted complementary policies that promote innovation, 
facilitating south-south or north-south technology transfer and providing preferential 
financial incentives for investors in this area.   
The below policy options are set for consideration by the government in order 
to maximize efficiency of regulatory interventions pertaining to the 
biopharmaceutical sector and particularly to biosimilars: 
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I. Policy options to ensure quality, safety and 
efficacy of biopharmaceuticals / Biosimilars in the 
Egyptian Market 
A. Bridging the legislative gap on dealing with biosimilars registered as 
generics prior to the 297/2009 decree:  
A ministerial decree has to be issued to fill the current legislative gap on how 
to deal with biosimilars or standalone biopharmaceuticals registered as generics prior 
to the 297/2009 ministerial decree and current draft guidelines that regulates 
biosimilars.  
B. Proactively tackling re-registration requirements:  
This has to be managed on case by case basis on what quality, safety and 
efficacy data the product provided in the initial registration phase and what data 
needs to be generated and studies to be done in order to provide proof of safety, 
efficacy and quality. Considering the culture of reporting on adverse events in Egypt 
being in its early stages (EPVC established in late 2010) anecdotal evidence may be 
taken in to consideration for the quality, efficacy and safety profiles of the products 
during the  (10 years primary registration period) spent in  the market however 
studies following regulatory procedure according to international standards and 
requirements to ensure quality, safety and efficacy  have to take place based on 
assessment of the product risks and benefits. The depth and extent of such studies 
also will be dealt with according to the new requirements and depending on the 
current quality, safety and efficacy data available on the product. The regulatory 
structures involve (CAPA Biological registration, inspection departments and 
concerned NORCB departments) should start educating companies with products 
with about to expire registration license and whom are close to applying for re-
registration on what is the type of QSE data needed from them and put a time frame 
on generating such data through studies supervised by the responsible regulatory 
structures. 
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C. Continuing collaboration with stakeholder on draft registration guidelines:  
The current draft guidelines on regulations of biosimilars represents a 
positive step towards being proactive in tackling an upcoming regulatory challenge. 
The government is encouraged to continue the progressive regulatory thinking by 
meeting with manufacturers in feedback workshops and finalize the current version 
in a format agreed upon by majority of stakeholders. However there is an eminent 
need to back MOH with the required senior expertise in such meetings to avoid the 
pressure exerted by industry experts on mid-level government employees who 
usually run those meetings on behalf of CAPA. 
D. Strengthening National Regulatory Structures:  
The government should consider the fact that the presence of a legal and 
policy regulatory structures in place without the required qualifications and the right 
caliber is jeopardizing Public Health. Scientific expertise and nurturing regulatory 
talent is the main asset of regulatory authorities. The current recruitment system is 
dependent on an annual supply of around 200 pharmacists who should be employed 
as part of the government policy for compulsory service.  A competency based 
model for recruitment should be adopted rather than compulsory service distribution 
to retain the best regulatory talents. Recruitment on project basis may be adopted and 
salary scales has to be revised to fit with inflation and market rates.  Currently the 
salary of employees is  composed of (fixed 30% and a variable of 70% )which put 
them in a status of stress as the variable component can be removed any month due 
to the worsening economic condition, this affects their ability conduct their 
regulatory functions and may also affect public health outcomes. In order to achieve 
this level of autonomy has to be revisited and the Egyptian Drug Authority has to be 
autonomous on reality rather than on paper.  Currently 45% of the funds (revenue 
pool for licensing and registration) money goes to NRMA and the rest to MOH 35% 
and the ministry of finance 20% while they don’t contribute with any significant 
CAPA/NORCB operational costs.  
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E. Expediting clinical trials law:  
With the new biosimilars draft guidelines requiring companies to conduct 
their clinical trials is another legislative gap that exists implying the lack of a legal 
cover for the currently proposed regulations to conduct clinical trials in Egypt. Many 
of the industry representatives interviewed voicedout their concern that the absence o 
fsuch law will drive them to conduct the trials outside the country which impose 
significant costs. Such costs are unnecessary when a national law exists and may be 
factored in to pricing decisions leading to increase in biosimilars prices. The current 
draft law being under discussion has to be expedited for assessment as soon as a new 
parliament is elected. 
II. Policy options to increase efficiency in the 
registration process of biosimilars: 
A. Revisiting the box system 
The government may consider making it public for chemical based medicines 
and removing it for the local producers to encourage investment in local production. 
B. Increasing scrutiny in pricing committee decision 
The government may consider addition of a permanent member to the current 
pricing committee representing civil society groups interested in patient’s rights and 
access to medicines. 
C. Commissioning a Regulatory Impact Assessment study by a third party  
To assess the impact of the latest pricing decree one year after its 
promulgation on price of medicines, shortage and effect on local production and 
review the percentages to reach a mid-way between the retail pharmacists and 
producers.  
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III. Policy options to encourage investment in local 
production of Biosimilars:  
A. Subsidizing local biopharmaceutical manufacturers:  
Medicines are not a normal commodity they are inelastic in demand and this 
may lead to catastrophic health expenditures with a very high out of pocket payment 
level like in Egypt. Hence the government should focus on development of a strong 
base of local industry that is able to manufacture biosimilars for life saving and 
critical diseases at an affordable cost. The government may start thinking 
strategically about subsidizing local producers of biosimilars falling on the essential 
medicines list (like interferons, human albumin,etc..). Egypt has an opportunity with its 
reasonable foundation of manufacturers currently producing biosimilars. The opportunity 
exists to collaborate and develop joint ventures with some of the early adopters (India, 
Korea, China, Iran, Cuba, Argentina, etc…) to develop molecules that are about to lose 
patent protection and worth a total of 50 billion USD in annual sales (GEN, 2013)40. 
Subsidies may take the forms of financial and other incentives such as interest-free 
loans, preferential pricing over imported, free land, etc… The current practices of 
providing preferential treatment to local manufacturers at tenders should continue by 
providing lower fee for participation, giving favourable pricing (imported has to be at 
least 15% less than local). In addition tariffs and customs mark-ups may be further 
reduced. Currently a sales tax of 5% applies to different medicines categories (aside 
from the chronic and non-communicable disease medicines). 
B. Facilitating technology transfer: 
 Currently few of the producing biotech companies develop their own 
technology, some are dependent on technology transfer agreements with foreign 
manufacturers others are just filling or labeling the vials. Currently the government is 
not promoting technology transfer or making enough effort to be an attractive option 
to investors. This area due to its strategic considerations may need clear government 
policy and constant efforts to transmit the message to the private sector and facilitate 
                                                            
40
 http://www.genengnews.com/insight-and-intelligenceand153/biosimilars-10-drugs-to-
watch/77899804/  
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their investment, quoting an ex senior director of a governmental entity and currently 
CEO of one pharmaceutical manufacturer , “this area should be highly adopted on the 
Egyptian political agenda , it touches upon medicines that may affect national security 
especially in transfer of technology to produce life-saving products and vaccines”. The 
easier way to start is by looking south to Latin America or Asia with several main 
players like India, Iran and Cuba41. 
C. Bridging the regulatory gap on technology transfer:  
The government still doesn’t have guidelines for technology transfer were it 
may consider embarking on its development if it will open arms for investors to do it, 
it should know how and what it will regulate in it This is currently misleading and 
deterring  to  many investors considering to venture in to this area. 
IV. Policy options to preserve the TRIPS flexibilities 
in the current patent protection policy:  
The government of Egypt should realize that it is not yet hit with the effect of 
patents on access to medicines. This is simply because most medicines currently on 
patent were registered and in use prior to the 2005 promulgation of the patent law and 
due to the very flexible articles in the Egyptian patent law, many multinational 
companies were reluctant to file patent application in Egypt with around 161 patents 
filed. It is interesting to compare this figure with other developing countries. 
According to a South Center study in Argentina, 951 pharmaceutical patents were 
granted in 2000–2007; in Brazil, 278 patents were granted in 2003-2008; in 
Colombia 439 in 2004–2008; in India 2347 in 2005–2008; and in South Africa, 2442 
patents were registered in 2008 (Iskander,2012). However for all the new innovations 
post 2010 and this is mainly in the biopharmaceutical sector, the government will face 
aggressive pressure from countries of multinational corporations to introduce measures 
to increase patent protection like Data Exclusivity and otherTRIPS plus measures and 
even the current article on TRIPS flexibilities42 may be challenged as being non-TRIPS 
compliant due to their unclear wording and sometimes ambiguity on how they are 
                                                            
41
 government dedicated 80 acres compound for toxicological studies and testing of biotech products in animals   
42
 Articles 17 and 24 
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implemented. The government should send only qualified negotiators to negotiation 
rounds of bilateral or regional trade agreements. Qouting a senior executive of the 
Egyptian Patent Office “ In Free Trade Agreement rounds, if negotiators don’t have the 
required qualifications and understanding of the subject, signing a simple annex may be 
very easy , nevertheless implications will be devastating, leading to reduced access to 
affordable medicines, hampering local production and jeopardizing public health”. 
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Appendix -1 
 Proposed conceptual Model for resolving the identified gaps in the 
Egyptian government’s regulation of the Biopharmaceutical sector 
 
 
•Sending
•qualified negotiators to the free 
trade agreement (FTA) or any 
bilateral trade agreement 
negotiations that involve 
provisions on IP protection
•Review the patent law of Egypt to 
include terms clarifying the TRIPS 
flexibility articles of the law to 
strengthen it and reduce level of 
ambiguity and potential to be 
challenged as non TRIPS compliant
•Outreach to local producers and 
investors on the current legal 
rights given by the law 82/2002 to  
grant voluntary and non voluntary 
licenses to begin local 
manufacturing of public health 
priority products 
•Increase governmentsubsidy to 
local biopharmaceutical 
production in forms of financial 
(owning small shares) , infra 
structure or preferential pricing.
•Facilitating technology transfer 
by using political support to link 
with advanced players from the 
developing countries such as 
Iran, South Korea , India and 
Cuba.
•Focus on key biological products 
with soon to expire patents and 
which serves local disease 
burden
•Bridgethe regulatory gap in 
technology transfer  guidance to 
investors in the area
•Revisiting the box system in
registration process of
biopharmaceuticals and chemical
medicines
•Increase scruiting in pricing
committee decision making
process
•Commissionin ga neutral third
party regulatory impact
assessment study in Pricing decree
499/2012
•Briding the legislative gap in dealing 
with biosimilars registered before as 
Generic chemical medicines
•Proactively tackling re-registration 
requirments
•Continue the practice of collaboration 
with stakeholders in designing the 
guidelines for registration 
•Strengthening National Regulatory 
Authorities
•Expediting a clinical trials law 
•Enhancing the level of dialogue between 
government and different interest 
groups within the biopharmaceutical 
regulatory arena to 
•Avoid rent seeking behavior and align 
view points with national strategic 
objectives
Policy options to 
ensure quality, 
safety and 
efficacy of 
biosimilars in the 
Egyptian Market
Policy options to 
increase 
Efficiency in the 
registration 
process of 
biosimilars
Policy options 
to preserve the 
TRIPS flexibilities 
in the current 
patent protection 
policy
Policy options to 
encourage 
investment in 
local production 
of biosimilars
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Appendix -2 
Questionnaire for Expert interviewees 
Regulatory framework: 
1- Please list the Decrees on regulations , pricing and clinical trials of Biosimilar 
products 
2- How many Biological products are registered? What about those registered 
before 2009 
3- How many are biosimilars or non-vaccines or blood products? 
4- How many are locally manufactured?   
5- How do you perceive the process of registration of biological products prior to 
2009 decree on establishing a biological registration department in terms of 
ensuring quality, safety and efficacy?  
6- How do you compare it to Global Best Practices 
7- How many biosimilars are under application for registration (from the time of 
2009 guidelines-present)?   
8- Were their registration deferred until the final guidelines are ratified?  
9- How do you ensure GMP compliance if you don’t inspect source of Active 
Pharmaceutical Ingredient? Adequacy versus SRA guidelines? 
Challenges in Regulating biosimilars 
10- What are the general challenges in regulating such market in Egypt? 
11- How do you plan to deal with products registered before 2009to reduce risk on 
the society from such products?  
12- If registration status review at time of re-registration is the envisaged solution. 
When product suspension happen at time of re-registration, do you expect the 
process will continue? How do you think this will affect patient’s access? 
PharmacoVigilance/Adverse Drug Events Reporting: 
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13- When was the National system for tracking adverse drug events established in 
Egypt? 
14- How many reports were received? Were any reports related to biological 
products? 
15- How many companies have a system to track adverse events from products in 
the market and when was it established?  
Reimbursement/ Health Insurance: 
16- Which hepatitis C interferons are on the list of the formulary for reimbursement 
by Health Insurance?  
Procurement: 
17- How are medicines procured for public institutions in Egypt? How much is the 
annual procurement budget for medicines? How much  of it is for biological?  
18- How much is for Hepatitis C virus interferon treatment? 
Special interest Groups: 
19- How do you perceive the role of the chamber of industry lobby in affecting the 
current pricing law? 
Pricing related questions:  
20- How are medicines priced and why are biological products of higher price tags 
than normal chemical based products? 
21- Do you plan to include value based pricing in your  future pricing policy? Do 
you think the registration committee has the scientific capacity to assess 
pharmacoeconomic studies to establish a price to the value of product? 
22- Are there any taxes levied on raw materials in preparation of medicines or 
biosimilars? 
23- Are there any taxes levied on the final finished products 
IP related questions: 
24- How do you ensure bio-similar products submitted for registration are not 
infringing patents? Do you cooperate with EPO? Please elaborate eon such 
cooperation 
25- Do you have cases for patent disputes of medicinal or biological products in 
Egypt? If yes how many in 2012-2013? 
26- What is the normal legal route taken in case of a dispute? 
27- Is data exclusivity part of the Egyptian Patent Law? When was last 
amendment? If not do you think it is envisioned for being integrated to the 
patent law? 
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28- What do you think the role of data exclusivity will play on the number of 
biosimilar products?  
29- Do you have other information which you want to add and you think are 
useful in my research ? 
 
Market Failures: Do you feel the current regulatory policy for biosimilars allow 
for any possible loopholes for any form of market faliures as below 
A. Externalities: positive or negative 
B. Information Asymmetry 
C. Monopolies 
For industry: 
30- How do you perceive the market for biosimilars in Egypt in the next 5 years? 
Market Growth and profitability? 
31- How many companies do you think will plan to introduce biosimilars to the 
Egyptian market? 
32- How do you perceive the registration process in Egypt for biologicals in 
particular? 
33- Do you think there is a level of information asymmetry in the regulatory 
process of biosimilars in Egypt? 
34- How do you perceive the licensing procedure for investors in the area of 
biological or biotechnological production? 
35- Are there any taxes levied on raw materials in preparation of medicines or 
biosimilars? 
36- Are there any taxes levied on the final finished product? 
37- How about other government policies in the field of R&D promotion for such 
products? 
 
